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ABSTRACT 
Catherine R. Lesko: The Population Level Impact of HIV Treatment in the Test-and-Treat Era 
(Under the direction of Stephen R. Cole) 
 
Antiretroviral therapy (ART) reduces mortality and prevents secondary transmission of 
HIV. Treatment guidelines now recommend initiating ART immediately following HIV 
diagnosis. The impact of this test-and-treat strategy on survival among HIV-infected persons in 
the United States (US) is unknown. First, published estimates of the effect of ART have been 
based on cohorts that are not representative of this target population. Second, evidence as to 
whether racial/ethnic/sex disparities in survival persist following ART initiation is mixed. 
In this dissertation, I estimated 5-year mortality risks for ART initiators versus non-
initiators among 12,547 patients in the Centers for AIDS Research Network of Integrated 
Clinical Systems (CNICS) using the complement of weighted Kaplan-Meier survival functions. I 
subsequently standardized estimates to persons diagnosed with HIV in the US between 2009 and 
2011, enumerated using national surveillance data from the Centers for Disease Control and 
Prevention. Furthermore, I calculated the 10-year all-cause mortality risk among 10,017 ART 
initiators, stratified by race/ethnicity and sex, from weighted Kaplan-Meier survival functions. 
The 5-year mortality among ART initiators in the CNICS was 10.6% (95% CI: 9.3%, 
11.9%) compared to 28.3% (95% CI: 19.1%, 37.5%) among non-initiators. ART initiation 
lowered 5-year mortality by -19.1% (95% CI: -30.5%, -7.8%) among recently HIV-diagnosed 
persons in the US. This effect was similar to the effect of ART estimated in the CNICS (risk 
difference: -17.7%, 95% CI: -27.0%, -8.4%). The overall 10-year mortality risk among ART 
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initiators was 20.2% (95% confidence interval (CI): 19.2%, 21.3%). Black men and women 
experienced standardized 10-year all-cause mortality risks that were 7.2% (95% CI: 4.3%, 
10.1%) and 7.9% (95% CI: 3.9%, 12.0%) larger than white men. White women, Hispanic men, 
and Hispanic women all had lower 10-year mortality than white men.  
ART initiation substantially lowers mortality among persons in the CNICS and this 
benefit is expected to be similar among persons recently diagnosed with HIV in the US. 
However, survival following ART initiation differs by race/ethnicity. Effective interventions are 
needed to ensure that the goal of the National HIV/AIDS Strategy to overcome health disparities 
becomes a reality.  
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CHAPTER 1: SPECIFIC AIMS 
 
Initiation of combination antiretroviral therapy (ART) by those infected with HIV 
improves survival and reduces HIV transmission.1-3 Following confirmation of the transmission-
prevention benefits of ART, treatment guidelines were recently updated to recommend ART for 
all HIV infected individuals, regardless of clinical status.4 The expected effect of this new policy 
on survival among persons recently diagnosed with HIV in the United States (US) is poorly 
quantified because existing estimates of the effect of ART have been based on cohorts that are 
not representative of this target population.5-7 Namely, cohorts have been primarily European 
(and receiving care under a different health care system) and have excluded persons with AIDS 
at baseline, despite the fact that 26% of persons diagnosed with HIV in the US receive a 
diagnosis of AIDS simultaneously or within 3 months of their HIV diagnosis.8 Additionally, 
differences in the age, race, sex, and risk group distribution between clinical cohorts and persons 
recently HIV-diagnosed in the US may result in different estimates of the population effect of 
ART, to the extent that heterogeneity in the effect of ART is associated with these 
characteristics. Furthermore, while disparities in survival among HIV infected people in the ART 
era are well documented,9-12 they may be associated with simultaneous disparities in access to 
ART.13,14 Reducing disparities in outcomes among HIV-infected persons is a key goal of the 
National HIV/AIDS Strategy, yet it is unclear whether disparities arise following ART initiation 
or whether disparities in survival are simply persisting across the care continuum, having arisen 
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in earlier stages.15-19 Understanding the potential population level impact of HIV treatment in the 
test-and-treat era is the overall goal of this thesis. 
The specific aims of this dissertation are to:  
1) describe the effect of ART initiation (versus not) on the 5-year risk of all-cause mortality 
in Center for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort 
and generalize this estimate to persons recently diagnosed with HIV in the US; and 
2)  describe differences in the 10-year risk of all-cause mortality following initiation of ART 
in the CNICS clinical cohort by race/ethnicity and sex. 
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CHAPTER 2: BACKGROUND 
 
2.1.  Significance 
Effective combination antiretroviral therapy (henceforth ART) improves survival among 
HIV-infected persons. After the introduction of ART (compared with mono- or dual-therapy) in 
1997, mortality among HIV-infected persons fell sharply compared to pre-1997 and continued 
falling as more people were prescribed ART and regimens continued to improve.20 Controlling 
for the health status of patients initiating ART, ART was estimated to reduce the mortality rate 
by 62%,21 although early observational estimates of the effect of ART were biased by time-
varying confounding. Improvements in epidemiologic methods (specifically, the development 
and application of marginal structural models) led to improved estimates of the relative reduction 
in the mortality due to ART: an 86% relative reduction in the mortality hazard for ART 
compared to no treatment [hazard ratio (HR)=0.14 (95% Confidence Interval (CI): 0.07, 0.29)] in 
the Swiss HIV Cohort Study;22 a 52% relative reduction in the mortality hazard in a 
collaboration of 12 cohort studies from Europe and the US [HR=0.57 (95% CI: 0.49, 0.67) at 1 
year after ART initiation, and HR=0.21 (95% CI: 0.14, 0.31) at 5 years after ART initiation];3 
and a 46% relative reduction in the hazard of AIDS or death among US participants in the 
Multicenter AIDS Cohort Study (MACS) and  Women’s  Interagency  HIV  Study (WIHS) 
(HR=0.54; 95% CI: 0.38, 0.78).23  
Differences in the effect estimates of ART may be attributable to differences in the health 
care systems in which the cohorts received care, as well as to differences in patient demographics 
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and baseline clinical characteristics that modify the effect ART on mortality.3 None of these 
existing estimates of the effect of ART are based on studies that reflect the demographics, 
clinical status and treatment experiences of the current US HIV-infected population, however. 
Clinical cohorts tend to be disproportionately white and male, when compared with the 
demographics of the US HIV-infected population (Table 2.1). The Swiss HIV Cohort Study22 
participants HIV-CAUSAL Collaboration3 participants are predominantly European and differ 
from the US HIV-infected population on demographics and treatment experience. Men in the 
MACS and women in the WIHS are demographically distinct from the US HIV-infected 
population.23 None of the three existing studies included persons with AIDS at baseline, despite 
the fact that 26% of all persons newly diagnosed with HIV in the US receive an AIDS diagnosis 
within 3 months of their HIV diagnosis.24 
Assuming effect heterogeneity of ART on survival, published estimates of the effect of 
ART on mortality reduction are not directly generalizable to the US population. The most recent 
estimates of the effect of ART on survival may be internally valid estimates (equal to the true 
effect of ART on mortality within the source population for the study), but even under these 
ideal circumstances, none of them may equal the average treatment effect that would have been 
observed if we had estimated the effect of ART in the target population, i.e., the persons recently 
diagnosed with HIV in the US. Results obtained in one sample may not generalize to another 
target population due to differences in the distribution of effect modifiers in the sample and 
target population (results may also be due to differences in treatment-versions or interference 
patterns between the study sample and target population).6,7 Reweighting of an estimate of effect 
from a study sample to match the distribution of effect modifiers in a specified target population 
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yields an estimate of effect for the target population.5 This is a semiparametric extension of 
direct standardization.  
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Table 2.1. Characteristics of cohorts used in prior estimates of the effect of antiretroviral therapy on mortality, persons enrolled in the 
Center for AIDS Research Network of Integrated Clinical Systems (CNICS) during 1998-2012, and persons diagnosed with HIV in 
the United States, 2009-2011 
HIV-diagnosed in 
the US, 2009-
2011e 
128,945 
 
36,635 (28) 
60,516 (47) 
26,079 (20) 
5,715 (4) 
 
100,819 (78) 
28,126 (22) 
 
 
25,535 (20) 
35,625 (28) 
31,153 (24) 
25,030 (19) 
11,602 (9) 32,896 (26) 
10,429 (8) 
81,907 (64) 
4,105 (3) 
 
 
 
 
 
 
 
(32) 
(39) 
(28) 
CNICS Study 
Sample at 
Enrollmentd 
12,457 
 
5,539 (44) 
4,789 (38) 
1,635 (13) 
584 (5) 
 
10,265 (82) 
2,282 (18) 
 
38 (31, 45) 
980 (8) 
3,731 (30) 
4,766 (38) 
2,471 (20) 
599 (5) 2,343 (19) 
2,343 (19) 
7,509 (60) 
903 (7) 
 
4.5 (3.5, 5.1) 
2,037 (14) 
3,297 (22) 
9,661 (64) 
 
338 (142, 542) 
4,724 (32) 
3,026 (20) 
7,245 (48) 
HIV-CAUSAL 
Collaboration, 
AIDS, 2010c 
62,760 
 
 
 
 
 
(74) 
(26) 
 
 
30,990 (49)g 
 
25,743 (41)i 
 
6,027 (10)k 0 (0) 
7,964 (13) 
24,342 (39) 
 
 
4.5 
 
 
 
 
390 
518 (16) 
772 (24) 
1,955 (60) 
Sterne et. al., 
Lancet, 2005b 
3,245 
 
 
 
 
 
 
2,144 (66) 
1,101 (34) 
 
 
720 (22)f 
 
1,699 (52)h 
575 (18)j 
251 (8)k 0 (0) 
1,114 (34) 
926 (29) 
 
 
 
427 (13) 
1,232 (38) 
1,586 (48) 
 
 
 
 
  
Cole et. al., AJE, 
2003a 
1,498 
 
561 (37) 
 
 
 
 
506 (44) 
992 (66) 
 
39 (33, 44) 
 
 
 
 
 0 (0) 
 
 
 
 
4.5 (4.0, 5.0) 
422 (28) 
272 (18) 
804 (54) 
 
395 (257, 560) 
258 (17) 
373 (25) 
867 (58) 
  
Total N 
Race/ethnicity 
   White 
   African-American 
   Hispanic 
   Other 
Sex 
   Male 
   Female 
Age  
   Median age (IQR) 
   18-24 years 
   25-34 years 
   35-44 years 
   45-54 years 
   ≥55  years Hx of AIDS at 
baseline IDU (incl. MSM) 
MSM (incl. IDU) 
MSM & IDU 
Baseline VL 
(copies/mL) 
   Median (IQR), log10  
   ≤400 
   401-10,000 
   >10,000 
Baseline CD4 
(cells/μL) 
   Median (IQR) 
   <200 
   200-350 
   >350 
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a Only 60% of persons were mono-therapy or combination ART naïve at baseline and all were AIDS free. 
b Only 68% of persons were mono-therapy or dual-therapy naïve at baseline and all were AIDS free. 
c The HIV-CAUSAL collaboration comprises 12 prospective cohort studies from 5 European countries (UK, France, Netherlands, 
Spain, Switzerland) and the US (VACS-VC). 
d Includes ART-naïve (no documented mono- or dual-therapy, and detectable baseline viral load) patients who established care, 
defined as attending at least 2 clinical care visits, at a CNICS site between 1 January 1998 and 30 December 2011. Excludes patients 
with missing race/ethnicity or transmission risk category. 
e US newly HIV-diagnosed population includes individuals age 13-18, whereas CNICS eligibility criteria include age ≥18  years.  
Adolescents are expected to make up a very small proportion of the US newly HIV-diagnosed population and thus the influence on 
generalization should be minimal. 
f 15-29 years 
g <35 years 
h 30-39 years 
i 35-50 years 
j 40-49 years 
k >50 years 
l Estimated from persons newly HIV-diagnosed in 2011 in 18 states (Delaware, Iowa, Indiana, Kentucky, Missouri, Nebraska, New 
York State (excluding New York City), North Dakota, San Francisco, South Carolina, West Virginia, Wyoming) and DC where CD4 
cell counts are reportable; 26% of newly diagnosed individuals had no CD4 count performed and reported within 3 months of 
diagnosis. 
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The US HIV epidemic is characterized by racial and ethnic disparities. The HIV epidemic 
has evolved dramatically since it first emerged in 1981. Whereas it was once considered a 
disease of white men who have sex with men (MSM), today African-American and Hispanic 
men and women are disproportionately impacted.25,26 In 2010, as in previous years, HIV was one 
of the top five causes of death among African American men and women age 25-44.27  The HIV 
care  continuum  is  a  convenient  framework  describing  patients’  progress  from  HIV  infection  to  
treatment and viral suppression, and is used frequently for situational awareness of the HIV 
epidemic.28,29 About 64% of the HIV-infected US population is lost somewhere along the HIV 
care continuum prior to being prescribed therapy28,30 and losses are non-differential with respect 
to race, ethnicity, sex, and risk group, making the population presenting for HIV treatment 
different from the HIV-infected population.13,31-33 Minorities are more likely to be diagnosed 
later in the course of their infection, more likely to experience delays in entering HIV care 
following diagnosis, and less likely to receive ART once in care.13,15,31,32,34-39  
Evidence of demographic disparities in survival following ART initiation is mixed. 
Racial disparities in survival after ART initiation are difficult to disentangle from disparities in 
survival that have existed since the pre-ART era.9,40 The idea that the survival benefits of ART 
may not be equally experienced by all is supported by studies that reported reductions in 
mortality rates in the era of effective combination ART that were less dramatic among HIV-
infected black or Hispanic persons compared to white persons.9,41-43 However, other studies 
found no modification of the effect of treatment era by race.44  In the era of effective 
combination ART, survival after HIV diagnosis continues to be lower for black persons 
compared to white persons.45 Differential access to care and ART, rather than differential 
survival after ART initiation, has been postulated as a mediator of the association between race 
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and mortality. In support of this theory, researchers found no association between race and 
mortality among members of several cohorts with presumed equal access to care (i.e., the WIHS, 
persons continuously insured by Kaiser Permanente of Northern California who started ART, 
veterans, and patients initiating ART at a CD4  cell  count  >350  cells/μL).17,46-48 However, other 
studies have shown racial disparities of varying magnitude in survival regardless of access to 
care.49,50  
The evidence for disparities in survival associated with Hispanic ethnicity is weaker. 
Prior to the introduction of ART, the few studies that included survival estimates stratified by 
ethnicity reported no differences among Hispanic and white patients.9 Most studies that have 
been conducted among HIV-infected patients with equal access to care and among HIV-infected 
patients who started ART have found no association between Hispanic ethnicity and mortality 
rate.17,46,50 However, among participants in the WIHS on continuous ART, Hispanics had a 
higher, but imprecisely estimated, relative hazard of AIDS-related death compared to whites 
(HR=1.56, 95% CI: 0.88, 2.77).49  
Gender disparities in survival after ART initiation have been described less frequently. 
Perhaps because two of the three studies that mention investigating disparities by sex found no 
sex differences in survival due to ART use.23,51 However, in one pooled analysis of US and 
European cohorts, the relative hazard of death associated with ART initiation was 0.32 (95% CI: 
0.21, 0.50) among women, but only 0.52 (95% CI: 0.44, 0.62) among men.3  
 
2.2.  Innovation 
This is the first study to estimate the effect of ART on survival standardized to the US 
population. Thus far, estimates of the effect of ART have come from clinical cohorts that do not 
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reflect the heterogeneity of the US HIV-infected population or routine clinical care as delivered 
in the US. No existing studies of the effect of ART on mortality have included persons who had 
an AIDS diagnosis at baseline,3,22,23 despite the fact that 26% of persons newly diagnosed with 
HIV from 2009-2011 were diagnosed with AIDS within 3 months of their HIV diagnosis date.8 
Two of the three estimates of the effect of ART on mortality were based on HIV-positive cohorts 
that were entirely22 or predominantly European.3 Two of the three estimates have been based on 
cohorts that included HIV-infected patients in the US, however neither of the US-based cohorts 
had been representative samples; one estimate included patients from the VACS-VC3 and one 
estimate was based on participants in the MACS and the WIHS.23 The diversity of the CNICS 
cohort allows for estimation of stratified estimates of the effect of ART on mortality to reveal 
effect heterogeneity. Further, it is possible to estimate inverse probability of sampling weights 
for persons in the CNICS to generalize results to the US population since the probability of being 
sampled will be greater than 0 for persons of minority race/ethnicity and gender.  
To my knowledge, this is the first attempt to generalize an estimate of effect from an 
observational cohort to a target population other than the source population where the 
probabilities of selection into the sample are unknown. In all epidemiologic investigations, there 
is a target population to whom we would like to make inference, a source population from whom 
the study sample is drawn, and a study sample in whom we measure exposure, outcome, and 
covariates and estimate an effect.52 Inverse probability of exposure weighting is an established 
method for generating an internally valid causal effect in an observational study, i.e., of 
estimating the effect for the source population from the study sample when the treatment was not 
randomized.53 Inverse probability of exposure weights have previously been applied specifically 
to the estimation of the causal effect of ART from observational data using marginal structural 
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models.3,23 Generalizability weights, or inverse probability of sampling weights, can be used to 
generalize an estimate of effect from a source population to a specific target population. So far, 
such inverse probability of sampling weights have only been applied to generalize an estimate 
from a randomized controlled trial to a specific target population5 or to generalize an estimate 
from an observational study to a target population where the sampling weights were known.54 
This is the first observational study that would simultaneously address internal and external 
validity, combining both sets of estimated weights.  
This dissertation adds to the literature on HIV outcomes among persons who have 
initiated ART. Examining disparities within the care continuum framework is useful for 
identifying specific interventions to improve HIV outcomes overall. Only three prior cohorts 
have been examined with a focus specifically on the survival of HIV-infected persons who have 
initiated ART: the WIHS;46,49 the Flexible Initial Retrovirus Suppressive Therapies (FIRST) 
clinical trial;50 and a cohort of HIV-positive enrollees in Kaiser Permanente Northern California 
who initiated ART and were followed until they died, until disenrollment or until administrative 
censoring.17 None of these cohorts are representative of all HIV-infected persons in the US. No 
men are included in the WIHS, yet men make up over 80% of HIV-infected persons in the US. 
The level of surveillance in the FIRST trial does not match the level of surveillance in routine 
clinical care. Finally, only a minority of HIV-infected patients, even in care, have private 
insurance; 31% of HIV-infected persons in care in 1996 had private insurance55 and that 
proportion dropped to 16% from 2006-2012.56  
Finally, the size and diversity of the CNICS cohort allows for the description of 
heterogeneity in treatment outcomes between demographic groups that are underrepresented in 
smaller observational cohorts. The only information that exists about survival for HIV-infected 
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Hispanic persons comes from public health surveillance9 or administrative data,57 neither of 
which include treatment information to be able to distinguish disparities arising prior to initiating 
ART from disparities arising after initiating ART.  
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CHAPTER 3: DESCRIPTION OF THE DATA SOURCE 
 
3.1.  Centers for AIDS Research Network of Integrated Clinical Systems 
Both aims of this study were accomplished using data from the Centers for AIDS 
Research (CFAR) Network of Integrated Clinical Systems (CNICS).58 The CFAR network was 
established by the National Institutes of Health (NIH) to provide administrative and research 
support to AIDS research projects that might not otherwise be readily undertaken using 
traditional funding mechanisms. CNICS is a clinic-based research network developed to support 
population-based HIV research. Of 19 CFARs, located in academic and research institutions 
across the US, four were initially chosen to participate in CNICS when it was first funded in 
September 2006 through the NIH (R24 AI067039): Case Western Reserve University, 
Cleveland, Ohio; University of Alabama, Birmingham, AL; University of California, San 
Francisco, CA; and University of Washington, Seattle, WA. Four additional sites were later 
added: University of California, San Diego, CA; Fenway Community Health Center of Harvard 
University, Boston, MA; and Johns Hopkins University, Baltimore, MD (Figure 3.1). All sites 
have institutional review board approval. To further protect patient privacy, CNICS obtained a 
Certificate of Confidentiality from the NIH, CFAR sites submit data stripped of personal 
identifiers, and all data are submitted by secure, encrypted FTP to the CNICS data repository.58 
High quality epidemiologic studies have been based on data from individual CNICS clinics,59,60 
CNICS as a stand-alone cohort,61-63 and on data from larger collaborations to which CNICS 
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contributes, namely the North American AIDS Cohort Collaboration on Research and Design.64-
66 
 
Figure 3.1. Centers for AIDS Research Network of Integrated Systems Sites 
 
Source: http://www.uab.edu/cnics/cnics-sites  
 
The CNICS data are collected from electronic medical records at each of the sites. This 
may include both structured queries against an electronic database (e.g., for laboratory results) 
and manual abstraction of data from clinical notes or other non-standardized fields in the medical 
chart (e.g., for clinical diagnoses). While each site collects information differently, the CNICS 
consortium has established standards for terminology, formatting, data verification, and quality 
assurance procedures. The CNICS data repository contains detailed information on patient 
demographics [year of birth, sex, race and ethnicity categorized according to US Federal Health 
Resource and Services (HRSA) standards], risk factors for HIV transmission [categorized 
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according to the US Centers for Disease Control and Prevention (CDC) classification], 
laboratory measures (including results of CD4 T cell counts, and plasma HIV-1 RNA levels),  
antiretroviral treatment data, diagnosis data (AIDS-defining diagnoses defined by the CDC 1993 
case definition), and mortality data. Laboratory test results are uploaded directly from Clinical 
Laboratory Systems at each site. Medication data are entered into the electronic medical record 
by clinicians or prescription data are uploaded directly from pharmacy dispensing systems and 
verified through medical record review. Historical data on prior antiretroviral treatment and prior 
AIDS diagnoses are collected upon enrollment into the cohort.58 Data validation occurs both 
within individual CNICS sites prior to transmission of the data and at the centralized CNICS data 
repository, both at the time of submission and after data are uploaded into the CNICS 
repository.58  
The CNICS cohort includes HIV infected patients 18 years of age and older who initiated 
primary care (defined as attending at least two primary care visits) at any of eight CNICS sites 
after 1 January 1995. For these analyses, I included patients who enrolled in care at a CNICS site 
between 1 January 1998 and 31 December 2011, when patient follow up was administratively 
censored for analysis (patient follow up from one site was administratively censored on 15 
September 2010). Between 1,300 and 2,000 patients have enrolled in CNICS each year since 
1998, and before any additional exclusions, the CNICS cohort for these analyses included 23,543 
patients. 
 
3.1.1. Exposure Assessment 
Specific Aim 1: Medication data are entered into the electronic medical record by 
clinicians or prescription data are uploaded directly from pharmacy dispensing systems and 
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verified through medical record review. The effective combination ART initiation date was 
defined as the first day on which a patient was prescribed three or more antiretroviral 
medications, each for at least 30 days. 
Analyses of the Multicenter AIDS Cohort Study (MACS) data define ART as 1) use of 
two or more nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) in combination 
with at least one protease inhibitor (PI) or one non- nucleoside (or nucleotide) reverse 
transcriptase inhibitors (NNRTI); 2) use of one NRTI in combination with at least one PI and at 
least one NNRTI; 3) a regimen containing ritonavir and saquinavir in combination with one 
NRTI and no NNRTIs; or 4) an abacavir-containing regimen of three or more NRTIs in the 
absence of both PIs and non-NRTIs. Analyses of the Women’s  Interagency  HIV  Study  (WIHS) 
definition for ART is any 3-drug regimen, one of which is a PI, a NNRTI, one of the NRTIs 
abacavir or tenofovir, an INSTI (raltegravir), or an entry inhibitor (maraviroc or enfuvirtide). The 
3+ drug definition of ART used in these analyses is a simpler definition than the ART definition 
used by the MACS or the WIHS, but there is considerable overlap between all three. While there 
is the potential that the simpler 3+ drug definition may classify some individuals as on ART who 
would not meet the ART definition for MACS or WIHS (potentially less than perfect 
specificity), 3+ drug regimens that do not meet the MACS or WIHS definition are rare, and all 
individuals meeting the definition of ART for MACS or WIHS would be classified as on ART 
under the 3+ drug definition (perfect sensitivity). The 3+ drug definition is a definition that has 
been used before and I am trusting that physicians that prescribe at least 3 antiretroviral drugs 
will have prescribed a recommended regimen. 
ART use is highly prevalent among CNICS patients, with approximately 1,200 to 1,400 
patients initiating a regimen containing at least 3 drugs each year. Overall, 77% of CNICS 
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patients initiated ART at some point prior to enrollment in CNICS or during follow-up, the 
probability of initiating ART by 10 years following CNICS enrollment went up to 90% when 
patients were censored at drop out, defined as going 1 year without having a CD4 cell count or 
viral load measurement (Figure 3.2). The most common initial regimen in 1998 was a triple 
nucleoside reverse transcriptase inhibitor (NRTI) regimen. By the end of the study period, the 
most common initial regimens were boosted protease inhibitor (PI) regimens and non-nucleoside 
reverse transcriptase inhibitor (NNRTI) regimens (Figure 3.3).  
 
Figure 3.2. Proportion of all CNICS patients initiating ART by time since enrollment, 1998-
2011, a) censoring at end of administrative follow-up only, and b) censoring patients after 1 year 
with no laboratory measurements (drop out) 
a) b) 
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Figure 3.3. Initial ART regimens for CNICS patients initiating ART by year of enrollment, 1998-
2011 
 
 
Specific Aim 2: In Specific Aim 2, the main stratification factor of interest was the cross-
classification of race/ethnicity and sex. Race and ethnicity were categorized according to US 
Federal Health Resource and Services Administration standards. For all aims of this study, race 
and ethnicity were combined into one variable, with patients classified as Hispanic, (non-
Hispanic) black, white, or other race. Sex was defined based on birth sex, or present sex if birth 
sex was missing. Two CNICS sites do not collect birth sex. Birth sex was not missing for any 
patients at sites that collect it. The proportion of patients for whom birth sex was not equal to 
present sex ranged from 0.32% to 2.6% in sites that collected both.  
The majority of CNICS patients are male (82%) and white (45%), followed by black 
(37%) and Hispanic (13%). 
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3.1.2. Outcome Assessment  
The outcome for both aims of this study was total mortality. Mortality information was 
obtained from clinic sources, death certificates, and regular queries to the Social Security Death 
Index. Different sites follow different query schedules, with the typical query schedule being 
every 6 months. As of December 31, 2011 (or September 1, 2010 at one clinic), 3,366 patients 
were known to have died since initiating care in the CNICS cohort (Figure 3.4). Among patients 
known to have died, the median time from CNICS initiation to death was 2.9 years (IQR: 1.1 – 
5.4 years).  
 
Figure 3.4. Crude mortality among all CNICS patients by time since enrollment, 1998-2011 
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3.1.3. Covariates 
 Age was defined at the time of origin for each specific aim: at CNICS enrollment for Specific 
Aim 1 and at ART initiation for Specific Aim 2. In all instances, age was calculated from 
mid-year of the reported birth year to the relevant origin date for each of the aims.   
 Calendar date of CNICS enrollment was recorded as the date of the second HIV primary care 
visit at a CNICS site. Patients must attend at least 2 HIV primary care visits before they are 
enrolled in in the CNICS cohort, therefore the date of HIV primary care initiation is not the 
same as the date of CNICS enrollment. Thus patients who die before attending a second HIV 
primary care visit and patients who are not retained in care until they can attend a second 
HIV primary care visit are excluded from these analyses and no information is available to 
conduct sensitivity analyses to determine the potential impact that exclusion may have on the 
final results of this study. 
 CD4 cell count was reported by the laboratory in cells/mm3. CD4 percent was also reported 
by CNICS laboratories but was not used in these analyses. CD4 cell count was not available 
in only 0.5% of all instances where a CNICS patient had a CD4 laboratory assessment. 
 HIV-1 RNA viral load was reported by the laboratory in copies/mL and transformed to units 
of log10 copies/mL. The limit of detection was dependent upon the assays used at each of the 
CNICS sites and changed over time. For this analysis, HIV-1 RNA values that were below 
the limit of detection were assigned a value equal to the limit of detection for the assay (i.e., a 
result  of  “<50  copies/mL”  was  assigned  a  value  of  50).   
 Antiretroviral therapy naivety was defined as no evidence of prior exposure to mono or dual 
therapy. If the earliest date of exposure to any antiretroviral drug matched the earliest date of 
exposure to at least three antiretroviral drugs, the patient was classified as ART naïve.  
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 AIDS-diagnoses were made at the CNICS site (57%), reported by the patient without outside 
documentation (18%), or were collected from outside documentation (19%). The remaining 
5% of AIDS-defining diagnoses were from unknown sources. If the diagnosis date was 
missing the day of the month, the diagnosis was assigned to the middle of the month. If the 
diagnosis date was missing both the day and month, it was assigned to July 1 of the year in 
which it occurred. Diagnoses that were missing the year were not assigned to the patient.  
 Male-to-male sexual contact and injection drug use were collected as part of risk factor data 
that was not assigned a date of initiation or cessation. Patients for whom injection drug use 
was ever recorded were assigned injection drug use as a time-independent covariate. Patients 
for whom male-to-male sexual contact was ever recorded were assigned male-to-male sexual 
contact as a time-independent covariate. Fifty-eight percent of patients report male-to-male 
sexual contact and 18% report a history of injection drug use. 
 Diagnoses of hepatitis C virus (HCV) infection were made at the CNICS site (67%), reported 
by the patient without outside documentation (14%), or were collected from outside 
documentation (15%). The remaining 4% of AIDS-defining diagnoses were from unknown 
sources. If the diagnosis date was missing the day of the month, the diagnosis was assigned 
to the middle of the month. If the diagnosis date was missing both the day and month, it was 
assigned to July 1 of the year in which it occurred. Diagnoses that were missing the year 
were not assigned to the patient. 
 
3.2.  United States Public Health Surveillance for HIV 
 HIV surveillance in the US is coordinated by the Division of HIV/AIDS Prevention in the 
CDC. In 1985, many state and local health departments began requiring (through administrative 
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rules) hospitals, laboratories, and physicians to any evidence of HIV infection in a person in their 
jurisdiction. It was not until 2008 that all states, the District of Columbia, and 6 US-dependent 
areas (American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Republic of Palau, and 
the US Virgin Islands) required confidential, name-based reporting of all HIV infection. State 
and local jurisdictions investigate and confirm reports of HIV infection, and then transmit de-
identified case reports to the CDC using a standard surveillance form. The surveillance form 
includes information on patient demographics (e.g., sex, race/ethnicity, age) and transmission 
risk category. When available, initial immune status (i.e., CD4 cell count) and viral load are also 
collected and reported to the CDC. Some jurisdictions additionally require reporting of all (or a 
subset of) CD4 cell count and viral load laboratory tests results for HIV-infected persons, which 
they use to monitor HIV disease progression. Treatment and other clinical data for all HIV-
infected persons are not generally available to public health surveillance.  
 The CDC collects HIV infection case reports from the states, the District of Columbia, 
and the 6 dependent areas and does a crude check for duplicate reports. Duplicate cases (persons 
who have previously been HIV-diagnosed in another jurisdiction) are identified through the 
Routine Interstate Duplicate Review. CDC uses Soundex code  generated  by  the  patient’s  last 
name, birth date and sex to compare newly reported HIV cases with previously reported cases. 
CDC alerts the local public health agencies of possible duplicates and the agencies resolve the 
duplicates using identifiable information.67 
 After waiting for case reporting to be acceptably complete, the CDC analyzes and 
disseminates data on HIV infection for the US. CDC reports both unadjusted and adjusted data. 
The unadjusted data is exactly what is reported through the date of analysis. The adjustment to 
the data is an attempt to delays in reporting (of diagnoses and deaths) and missing transmission 
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risk category. The adjustments do not attempt to account for incomplete reporting. Adjustments 
for delays in reporting are based on stratum-specific reporting-delay distributions, which are 
calculated using a modified semiparametric life-table statistical procedure.68 CDC recommends 
that adjusted data be used in planning, resource allocation, and program evaluation.69  
The target population for Specific Aim 1 includes all persons over 18 years of age 
diagnosed with HIV between 1 January 2009 and 31 December 2011 in any of the 50 states, 
District of Columbia, or 6 US-dependent areas. The target population included 128,945 patients 
(Figure 3.5). 
 
Figure 3.5. Rates of diagnoses of HIV infection among adults and adolescents, 2011, United 
States and 6 US-dependent areas 
 
Source: http://www.cdc.gov/hiv/pdf/statistics_2011_HIV_Surveillance_Report_vol_23.pdf  
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3.2.1. Covariates 
For the purposes of surveillance, CDC defines transmission risk category as the most 
likely mode of HIV transmission.8 It is created using a hierarchical decision tree using all risk 
factor information reported by the patient. Transmission risk category is assigned as follows:  
1) Male-to-male sexual contact and injection drug use 
2) Male-to-male sexual contact (alone): includes men who had sexual contact with other 
men, and men who had sexual contact with both men and women, regardless of their 
stated sexual identity 
3) Injection drug use (alone): includes persons who received an injection, either self-
administered or given by another person, of a drug that was not prescribed by a physician 
for that person 
4) Heterosexual contact: includes persons who had heterosexual contact with a person 
known to have, or to be at high risk for (e.g., an injection drug user or a man who has sex 
with men), HIV infection 
Race and ethnicity are collected according to the Revisions to the Standards for the 
Classification of Federal Data on Race and Ethnicity laid out by the Office of Management and 
Budget in the Federal Register for 30 October 1997.70  
AIDS diagnoses became reportable in 1981, using the same surveillance system 
described above for HIV diagnoses. By 1986, all 50 states, the District of Columbia, and 6 US-
dependent areas had implemented AIDS case reporting. For the purposes of surveillance 
currently, AIDS is defined as documentation of an AIDS-defining condition (appendix 1) or 
either a CD4 cell count of <200 cells/μL  or  a  CD4  percentage  of  total  lymphocytes  of  <14.  
Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would 
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not, by itself, be the basis for a stage 3 (i.e., AIDS) classification. For the purposes of Specific 
Aim 1, AIDS at  ‘baseline’  was  defined  as  having  an  AIDS  diagnosis  date  within  3  months  of  the  
HIV diagnosis date reported to HIV surveillance.  
 
3.2.2. Limitations 
Not all HIV diagnoses are included in the HIV surveillance data. Some states still offer 
anonymous HIV testing and positive test results are not included in surveillance data if no 
personal identifiers are available to allow for deduplication of case reports. Nationally, as of 
about 2006-2007, completeness of HIV case ascertainment was estimated at between 72% and 
95%.71,72  
Additionally, because confidential, name-based reporting was not fully implemented 
across all state and local jurisdictions until 2008, some persons reported as newly HIV diagnosed 
may actually have been previously diagnosed. If their previous diagnosis was not reported, or 
reported anonymously under older, code-based systems, any subsequent HIV test will appear to 
be a new diagnosis without proper investigation by state or local public health officials.  
Finally, the HIV diagnosis date reported to surveillance may not be entirely accurate. The 
year of the HIV diagnosis date reported to surveillance and the HIV diagnosis date reported by 
the patient in an interview differed in 56% of date pairs nationally, with the self-reported date 
likely to be the earlier date in 30% of the date pairs.73 In North Carolina, the year of the HIV 
diagnosis date self-reported by the patient matched the year of the HIV diagnosis date recorded 
in the medical record and the year of the HIV diagnosis date reported to HIV surveillance in only 
67% of cases and 51% of cases, respectively, where both dates were available. The self-reported 
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date most likely to be the earliest date of the three and the date reported to surveillance was most 
likely to be the latest date.74  
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CHAPTER 4: METHODS 
 
4.1.  Specific Aim 1 
 
4.1.1. Study Sample 
The study sample for Specific Aim 1 included ART-naïve patients who initiated care at a 
CNICS site between 1 January 1998 and 30 December 2011 (or 15 September 2010 for patients 
at one site). ART naivety was defined as no evidence of prior exposure to mono or dual therapy; 
patients whose earliest date of exposure to any antiretroviral drug precluded the earliest date of 
exposure to at least three antiretroviral drugs were excluded from the analysis. Furthermore, 
patients with missing race/ethnicity were excluded, as were patients classified as intersex, and 
patients missing data on transmission risk factors.  
The target population for Specific Aim 1, to which the estimate of the effect of ART was 
generalized, was all persons newly diagnosed with HIV in the US between 2008 and 2011. This 
population was diagnosed after the National HIV/AIDS Strategy was released, and was 
antiretroviral naïve as we entered an era in which the standard has shifted to providing treatment 
earlier in the clinical course of infection. The number of HIV-diagnosed persons in categories 
defined by race/ethnicity, sex, age group, transmission risk and AIDS diagnosis within 3 months 
of HIV diagnosis was provided by the CDC, Division of HIV/AIDS Prevention, and accounts for 
delays in reporting new infections.8 The marginal distribution of these characteristics is shown in 
Table 2.1.   
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The main exposure of interest, ART initiation, was defined as described in detail above, 
namely initiation of at least 3 antiretroviral drugs on the same day, for at least 30 days. I 
controlled for confounding due to the following baseline covariates: race/ethnicity; sex; age at 
CNICS initiation; calendar date of CNICS initiation; CD4 cell count (cells/mm3) and HIV-1 
RNA viral load (log10 copies/ml) at CNICS initiation or up to 6 months prior to CNICS 
initiation; history of injection drug use; history of male-to-male sexual contact; and study site. I 
further controlled for confounding due to the following time-varying confounder-mediators: 
history of diagnosis of any AIDS-defining condition; most recent CD4 cell count and viral load 
measurement; and ART use.  
Time-varying covariates, including CD4 cell count, viral load, AIDS diagnosis and 
hepatitis C virus infection, were updated whenever a patient was seen, with intervals determined 
by  medical  providers  and  by  patients’  care  seeking  behavior.  Laboratory  values  were  carried  
forward in time from the most recent observed value until new values were reported. Time since 
CNICS enrollment was categorized by month to create weights to control time-varying 
confounding. Time-varying covariates were assigned to the month in which they occurred. To 
preserve temporality, if a viral load measurement or an AIDS diagnosis occurred in the same 
month as, but more than 7 days after, ART initiation, the viral load measurement or AIDS 
diagnosis was assigned to the following month. If there was more than one CD4 cell count or 
viral load measurement in a particular month (after reassignment of viral load values), the values 
of all the measurements for that month were averaged. 
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4.1.2. Statistical Analysis 
Survival time was measured in days from CNICS enrollment to death. Patients were 
administratively censored on 31 December 2011 (or 15 September 2010 for patients at one site to 
ensure data completeness) or at 5 years of follow up. For patients missing baseline CD4 cell 
count or HIV-1 RNA viral load, follow up began on the earliest date that both of those 
measurements became available. This approach is akin to allowing late entries in survival 
analysis,75 and assumes late entries are non-informative.76  
To mimic an intent-to-treat analysis, once patients initiated ART, they were assumed to 
remain on treatment for the rest of their time on study. Patients were censored if they initiated 
any ART medications in a month without initiating three or more drugs (i.e., if they initiated 
mono- or dual-therapy). Patients who did not have any contact with the CNICS clinic (including 
therapy initiation or laboratory tests) over a 12-month period were censored 12 months after their 
last contact. Once patients were censored, they were not allowed to reenter the analysis. 
I estimated mortality risks, risk differences, and risk ratios using the complement of the 
weighted Kaplan-Meier survival function77 and described the relative hazard of mortality 
associated with ART use using a marginal structural Cox proportional hazards model, estimated 
using inverse-probability weights and using Efron’s  approximation  for  tied  death  times.78 
Weighting of the Kaplan-Meier survival function is accomplished using inverse probability 
weighting and is a semiparametric extension of nonparametric direct standardization to the total 
study population. I controlled for confounding and potentially informative loss-to-clinic in the 
estimate of effect in the CNICS with weights that were the product of: 1) stabilized inverse 
probability of treatment weights79,80; and 2) stabilized inverse probability of censoring weights.81 
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I standardized estimates to the target population by applying weights that are the product of the 
previous two weights and scaled inverse probability of sampling weights.5,7  
Treatment weights  XijW  and censoring weights  CijW  were estimated using pooled 
logistic models, with time defined by months since CNICS enrollment. The inverse probability 
of treatment weights were defined as:  
 
𝑤௜௝் =
∏ 𝑃൫𝑋௞ = 𝑥௜௞|𝑋(௞ିଵ) = 𝑥(௞ିଵ)௜, 𝐶௞ = 0൯௝௞ୀ଴
∏ 𝑃൫𝑋௞ = 𝑥௜௞|𝑋(௞ିଵ) = 𝑥(௞ିଵ)௜, 𝐿௞ = 𝑙௞௜, 𝑉 = 𝑣௜, 𝐶௞ = 0൯௝௞ୀ଴
 
 
Where 𝑋௞ is an indicator of treatment in month k; j denotes the number of whole months since 
the start of follow-up; and k indexes j so that the weights are specific to the person-month in 
which they are applied. 𝑋(௞ିଵ) is the history of exposure through month k-1, with 𝑋(ିଵ) defined 
to be 0. 𝐿௞ is the history of measured time-varying confounders through month k. V is the vector 
of time-fixed confounders measured at baseline. The inverse probability of censoring weights 
were defined as:  
 
𝑤௜௝஼ = ൞
∏ 𝑃൫𝐶௞ = 0|𝐶(௞ିଵ) = 0, 𝑋(௞ିଵ) = 𝑥(௞ିଵ)௜൯௝௞ୀ଴
∏ 𝑃൫𝐶௞ = 0|𝐶(௞ିଵ) = 0, 𝑋(௞ିଵ) = 𝑥(௞ିଵ)௜, 𝐿௞ = 𝑙௞௜, 𝑉 = 𝑣௜൯௝௞ୀ଴
, 𝐶௜௝ = 0
0, 𝐶௜௝ = 1
 
 
Where 𝐶௞ is an indicator of censoring in month k, j again denotes the number of whole months 
since the start of follow-up; and k again indexes j so that the weights are specific to the person-
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month in which they are applied. 𝐶(ିଵ) is 0 by definition. 𝑋௞, 𝑋(௞ିଵ), 𝐿௞ and V are defined as 
above.  
 Inverse probability of sampling weights were defined:  
 
𝑤௜ௌ = ቐ
𝑃(𝑆௜ = 1)
𝑃(𝑆௜ = 1|𝑉 = 𝑣௜)
, 𝑆௜ = 1
0, 𝑆௜ = 0
 
 
Where 𝑆 is an indicator of inclusion in the CNICS cohort and V is the vector of time-fixed 
confounders measured at baseline. 
I estimated the denominator of the inverse probability of sampling weights using a 
logistic regression model for the probability of being in the CNICS cohort based on the joint 
distribution of baseline covariates in the target population. The model included all second-order 
interactions. I scaled the weights by the marginal probability of being in the CNICS cohort. To 
correctly estimate the marginal probability of inclusion in the CNICS, I combined data from the 
CNICS and the target population, then weighted recently HIV-diagnosed persons (assumed to be 
a random sample of size m, of a hypothetical, arbitrarily large target population of size N) by 
1/[m/(N-n)], where n is the size of the study sample. I set N to be 1.1 million; the choice of N did 
not influence the results. Persons in the CNICS received a weight of 1. 
I multiplied all three estimated weights together and then applied the weights to a Cox 
proportional hazards model for the effect of ART on all-cause mortality. I used the same weights 
to estimate absolute and relative 5-year mortality from the inverse function of standardized 
survival curves.80,82  I explored changes in the estimates of effect after truncating the weights to 
reduce the effect of extreme outliers (<0.1 or >10).  
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The identifying assumptions necessary to conclude that the resultant estimated effect is 
internally valid include: 1) conditional exchangeability (no unmeasured causes of both the 
exposure and the outcome);83 2) positive probability of treatment within every level of covariates 
(positivity);84 3) treatment variation irrelevance;85 4)  no  interference  (when  one  person’s  
outcome is affected  by  another’s  exposure);86 5) no measurement error;87 and 6) correct models 
specification. These assumptions have been well described.79,83,88  
The generalizability assumptions necessary to conclude that the estimated effect is 
externally valid parallel the identifying assumptions for internal validity: 1) no unmeasured 
causes of both selection into the sample and the outcome; 2) non-zero probability of being 
included in the study sample; 3) treatment variation irrelevance or similar versions of treatment 
in the sample and the target;6 4) no measurement error; 5) no interference or similar patterns of 
interference in the sample and the target;6,86 and 6) correct models specification.5,89,90 Under 
these assumptions, weighting creates a pseudo-population in which the exposure is independent 
of measured confounders, censoring is independent of exposure and measured confounders, and 
the distribution of measured effect-modifiers matches that in the target population. 
I calculated 95% confidence intervals (CI) using a standard error estimated by the 
standard deviation from 200 nonparametric bootstrap random samples drawn from the study 
sample and the target population with replacement.91 All analyses were carried out using SAS 
9.3 (Cary, NC).  
 
4.1.3. Power 
Statistical power calculations for marginal structural models have not been developed. 
The precision for any survival model is dependent upon the number of events and, for weighted 
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survival models, on the variability in the weights. Prior applications of marginal structural 
models have been undertaken in smaller cohorts.23,92,93 Over 5 years of follow up, there were 918 
deaths among 12,457 patients in the study sample, and approximately 32% of the person-time 
was exposed to ART. With an expected hazard ratio of 0.5, the crude rate ratio under the 
proposed scenario would have an approximate variance of [1/(0.32*918) + 1/(0.68*918)] = 
0.0050 and an expected 95% confidence interval of 0.36, 0.64. The power for the naïve analysis 
was >99%.94 Incorporation of weights into the model inflates the variance. In prior applications 
of marginal structural models, the variance inflation factor has ranged from 1.1 to 2.0.23,95-98 A 
conservative assumption that the variance inflation factor could have been as high as 4, yielded 
an expected 95% confidence interval in the weighted model of 0.22, 0.78. This was associated 
with a power of 94%. The precision was expected to be lower for subgroup estimates, but the 
precision for the overall estimate suggested that I would have enough precision and statistical 
power to accomplish this aim. Details for the power calculation employed here are available in 
Appendix B.  
 
4.2.  Specific Aim 2 
 
4.2.1. Study Population 
The study population for Specific Aim 2 included patients who initiated a first 
combination ART regimen between 1 January 1998 and 30 December 2011 (or 15 September 
2010 for patients at one site). The origin was the date of ART initiation, defined as the first date 
when data indicated the patient was on 3 or more different antiretroviral drugs.  
34 
 
The cross-classification of race/ethnicity and sex was the exposure of interest. Race and 
ethnicity are categorized according to US Federal Health Resource and Services Administration 
standards. Race and ethnicity were combined into one variable, with patients classified as 
Hispanic, black, white, or other race. Sex was defined based on birth sex, or present sex if birth 
sex is missing.  
Race/ethnicity/sex specific survival curves were standardized to the distribution of the 
following covariates in the entire study population: age at ART initiation; calendar date of ART 
initiation; CD4 cell count (cells/mm3) most proximal to ART initiation measured between 6 
months prior to 14 days after ART initiation; HIV-1 RNA viral load (log10 copies/ml most 
proximal to ART initiation measured between 6 months prior to 14 days after ART initiation; 
antiretroviral therapy naivety (i.e., no evidence of prior exposure to mono or dual therapy); prior 
diagnosis of any AIDS-defining condition at ART initiation; injection drug use; history of 
hepatitis C virus (HCV) infection; and study site.  
 
4.2.2. Statistical Analysis 
Patients with missing race/ethnicity or patients with race/ethnicity other than white, 
black, or Hispanic were excluded, because the proportion of patients classified as other race was 
small, and interpretation of any results for this group would be difficult, given their 
heterogeneity. I additionally excluded patients classified as intersex, and patients missing data on 
the other covariates listed above. Characteristics of the study population was described using 
percentages or medians and quartiles, as appropriate.  
Survival time was measured in days from ART initiation until death or administrative 
censoring on 31 December 2011 or at 10 years of follow up to maintain adequate sized risk sets 
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(patients from one site were administratively censored on 15 September 2010 to ensure data 
completeness). I estimated the 10-year mortality risk using the complement of the Kaplan-Meier 
survival function77  standardized to the total study sample at the start of follow up.79,80 This is 
again a semiparametric extension of nonparametric direct standardization using inverse 
probability weights.99 I estimated the denominator of the weights for race/ethnicity and sex 
categories using polytomous logistic regression, conditional on all measured covariates listed 
above, using restricted quadratic splines (with 4 knots located at the 5th, 35th, 65th and 95th 
quantiles) to flexibly model all continuous covariates.100 Model fit was evaluated using a 
Hosmer-Lemeshow goodness-of-fit test for generalized logistic regression.101 I stabilized the 
weights using the site-specific distribution of race/ethnicity and sex.  
I calculated crude and standardized absolute and relative difference in mortality risk at 10 
years by race/ethnicity and sex categories. I calculated the relative hazard of mortality by 
race/ethnicity and sex categories with a Cox regression model102 using  Efron’s  approximation  for  
tied death times.78 I calculated Confidence Intervals using a standard error estimated by the 
standard deviation from 200 nonparametric bootstrap samples.91 I assessed the proportional 
hazards assumptions by visual inspection of a plot of the log cumulative hazard by time, as well 
as with a statistical test of the product terms for race and sex categories with time. Because 
unstabilized weights were poorly behaved, stabilizing by the site-specific distribution of 
race/ethnicity and sex was necessary. To examine the potential effects of residual confounding 
by site, in a supplementary analysis, I calculated site-stratified hazard ratios.  
To assess whether the magnitude of disparities in survival have changed over time, I 
stratified follow-up time into early and late calendar periods, varying the cut point from 2002 to 
2008 by increments of 2 years, and then tested the significance of interactions between time 
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period and race/ethnicity and sex in a Cox model. To assess how disparities observed in the 
CNICS compared with survival disparities seen in the US general population, I present age- and 
calendar time-standardized mortality rates for the general population, which I calculated from 
vital statistics data downloaded from CDC WONDER.103 To assess possible hypotheses about 
mechanisms for disparities in survival, I calculated the proportion of patients retained in care (no 
gaps in laboratory monitoring >1 year within 2 years of therapy initiation) and the proportion of 
patients who achieved and maintained viral suppression (defined as <400 copies/mL) at 1 year 
after therapy initiation, stratified by race/ethnicity and sex. Patients who died within the first 2 
years of follow-up without experiencing a gap in laboratory monitoring were considered retained 
in care. Patients who died before achieving viral suppression (1%) were considered not virally 
suppressed. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).  
 
4.2.3. Rationale  
 
Standardization:  
One might question the decision to standardize estimates at all, noting that there should 
be no confounding in the crude estimate (Figure 4.1.A). The argument against standardizing the 
estimate of association would be that: 1) I am not claiming to estimate a causal effect; or 2) a 
confounder is not something affected by the exposure and the covariates that I selected are 
typically thought of as being downstream from race (i.e., age at ART initiation may reflect 
differences in HIV incidence and in care seeking patterns among different racial/ethnic/sex 
subgroups). However, in this instance, interest is in heterogeneity in survival after ART 
initiation, and thus I have chosen to minimize variation in survival due to disparities before ART 
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is initiated. Differences in disease stage at ART initiation and subsequent ART use and 
adherence have been documented by race and ethnicity13,15,31,50 and by sex.15,34 Differences in 
disease stage at ART initiation should be controlled for in analyses seeking to estimate the effect 
of ART because they reflect differential access to care prior to exposure (Figure 4.1.B).104  
 
Figure 4.1. Directed Acyclic Graph for the 'effect' of race/ethnicity/sex on mortality among 
treated, HIV-infected persons 
 
 
Decision to not censor: 
Censoring patients when they stop treatment or leave the cohort estimates the association 
of race/ethnicity and sex with mortality conditional on remaining on treatment. If the association 
between  a  patient’s  decision  to  stop  ART  or  leave  the  CNICS cohort and his or her potential 
outcome is confounded, conditioning on remaining on treatment and in the cohort will result in a 
confounded estimate of the association of race/ethnicity and sex with mortality. Likewise, 
differences in adherence have been explored as a possible explanation for disparities in 
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mortality,18 and some studies support this hypothesis. Adjusting for time varying CD4, viral 
suppression, ART status and adherence negated observed racial/ethnic differences in hazard of 
death in a clinical trial50 and in an observational cohort.15 While such ad-hoc attempts at 
mediation analysis are potentially useful for hypothesis generation, noted problems with collider 
stratification bias in mediation analysis precluded us from exploring them in this study. I instead 
estimated the total association of race/ethnicity with mortality after ART initiation. 
 
4.2.4. Power 
Given the sample size, I had 80% power to detect a 10-year risk difference of 6.4% 
comparing black patients to white patients, a risk difference of 13.4% comparing Hispanic 
patients to white patients, and a risk difference of 7.8% comparing women to men.94  
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CHAPTER 5: RESULTS. THE EFFECT OF ANTIRETROVIRAL THERAPY ON ALL-
CAUSE MORTALITY IN THE CNICS, GENERALIZED TO PERSONS DIAGNOSED 
WITH HIV IN THE UNITED STATES, 2009-2011 
 
The magnitude of the survival benefit of ART among recently diagnosed persons in the 
US is unclear because existing estimates are derived from cohorts that differ substantially in 
terms of clinical status, race/ethnicity, age, transmission group and access to care.3,22,23 
Furthermore, the effect of ART appears to be heterogeneous across these same patient 
characteristics that differ between previously studied cohorts and recently HIV-diagnosed 
persons in the US.6,89 The objective of this aim was to estimate anticipated reduction in 5-year, 
all-cause mortality if all persons recently HIV-diagnosed in the US from 2009 to 2011 (the target 
population) had been prescribed ART immediately after diagnosis versus if treatment had been 
delayed. To accomplish this, I first described the effect of ART on survival in the CNICS clinical 
cohort, which is somewhat representative of, but not identical to, the target population. I then 
explored the impact of this residual non-representativeness by describing subgroup effects in the 
CNICS and presenting an overall estimate of the effect of ART reweighted to match the target 
population. A detailed description of the methods is available in section 4.1 of this document. 
 
5.1.  Results 
Overall, 12,457 patients in the CNICS met the inclusion criteria, most of whom were 
male and of white race (Table 5.1). The median age at CNICS initiation was 38 years old. The 
median CD4 cell count and viral load were 304  cells/μL  and  46,276  copies/mL,  respectively.  
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Nearly one fifth of CNICS patients had a history of an AIDS-defining illness at enrollment 
(18.7%). Injection drug use (18.7%) and hepatitis C virus co-infection were also common 
(14.0%).  
Patients were followed for a median of 32 months [Interquartile Range (IQR): 17, 60]. 
During 437,892 person-months of follow-up, 8,703 patients (69%) initiated ART, 5,390 patients 
(43%) were lost to clinic, and 918 patients died. Overall, 5-year mortality in the cohort was 
11.3% (95% CI: 10.5%, 12.0%).   
Predictors of ART initiation and censoring are listed in Table 5.2. Treatment and 
censoring weights were well-behaved and weight models using different functional forms of 
covariates yielded similar results for the effect of ART on survival.   
In the CNICS cohort, after accounting for time-fixed and time-varying confounding, 
ART lowered the absolute risk of mortality by -17.7% (95% CI: -27.0%, -8.4%; Table 5.4). The 
hazard ratio (HR) for all-cause mortality in the CNICS due to ART was 0.33 (95% CI: 0.25, 
0.43). The effect of ART on survival varied across subgroups of patients, although most 
subgroup effects were not statistically significantly different. The risk difference (RD) for 
mortality due to ART use was -14.4% (95% CI: -23.2%, -5.7%) among patients with no reported 
history of injection drug use, compared to -18.1% (95% CI: -31.8%, -4.4%) among patients with 
a history of injection drug use. ART was strongly protective against 5-year mortality for patients 
with lower CD4 cell counts at baseline and less protective as baseline CD4 increased [RD=-
29.3% (95% CI: -43.4%, -15.2%)  for  those  with  baseline  CD4  ≤200  cells/mm3 versus RD=-2.5% 
(95% CI: -6.0%, 1.0%) for those with baseline CD4>500 cells/mm3]. ART was also more 
strongly protective for patients with a prior AIDS diagnosis [RD=-22.8% (95% CI: -38.3%, -
7.3%)] than for those with no prior AIDS diagnosis [RD=-13.4% (95% CI: -21.3%, -5.5%)]. 
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Finally, among white patients, the RD for AIDS initiation was -17.3% (95% CI: -28.9%, -5.8%), 
compared to -11.3% (95% CI: -20.4%, -2.2%) among black patients and -10.1% (95% CI: -
21.8%, 1.6%) among Hispanic or Latino patients (Table 5.3). 
Compared to CNICS patients, more people diagnosed with HIV in the US during 2009 
through 2011 were women, Hispanic or Latino, or black. More recently HIV-diagnosed persons 
were diagnosed at younger or older age compared to CNICS patients at enrollment. More CNICS 
patients were diagnosed with AIDS at baseline and fewer had a history of injection drug use 
(Table 5.1). All covariates in the sampling model were strong predictors of inclusion in the 
CNICS (Table 5.2). Inverse probability of sampling weights were well-behaved. 
The effects estimated after standardizing to persons recently HIV diagnosed in the US 
using inverse probability of sampling weights were similar to those estimated in the CNICS. The 
estimated RD in the US was -19.1% (95% CI: -30.5%, -7.8%) and the HR was 0.32 (95% CI: 
0.23, 0.45) (Table 5.4). 
 
5.2.  Discussion 
 ART initiation substantially decreased 5-year mortality among patients in the CNICS. 
The effect of ART on mortality was heterogeneous across subgroups of patients defined by 
patient characteristics that were also predictors of inclusion in the CNICS. Despite the effect 
heterogeneity and differences between the study sample and the target population, the magnitude 
of the survival benefits of ART among recently HIV-diagnosed persons in the US were similar to 
those seen in the CNICS.   
Despite different study samples and inclusion criteria, the hazard ratio due to ART 
estimated in the CNICS is consistent with previously published estimates which have ranged 
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from 0.14 to 0.54.3,22,23 This analysis improves on previous studies estimating the effect of ART 
by presenting cumulative incidence curves and absolute differences in in risk, in addition to 
hazard ratios, which are arguably more useful to policy makers for planning.105,106 Furthermore, 
in this analysis I estimated the effect of ART on death alone, as opposed to the effect of ART on 
time to AIDS or death (this was also true in the most recent study).3 In the ART era, the risk of 
mortality following AIDS diagnosis is significantly reduced107 making death a more relevant 
clinical outcome. I excluded patients who were not ART naïve, consistent with current treatment 
standards.108 Finally, I included people with an AIDS diagnosis at baseline, in line with the 
reality that many patients are diagnosed with AIDS and HIV almost concurrently and will not 
have the opportunity to start ART before they are diagnosed with AIDS.24  
I was interested in estimating the effect of ART on all-cause mortality among recently 
HIV-diagnosed persons in the US. For an estimate from a study sample to directly generalize to a 
specific target population in expectation, either the study sample must be a random sample of the 
target population or those covariates that predict selection into the study sample must not also be 
causes of the outcome89,90 (in addition to assuming no interference86 and similar versions of 
treatment or treatment variation irrelevance).6 Because it was not logistically or financially 
feasible to randomly sample from the target population, I conducted the analysis in the CNICS. 
The CNICS cohort is similar to the target population on many structural factors, including the 
health care delivery system and social context. However, CNICS patients characteristics are still 
not identical to the characteristics of persons in the target population. We do not, as of yet, have 
a good understanding of the degree to which non-representativeness and non-significant 
departures from effect homogeneity across multiple subgroups may interact to produce changes 
in the final standardized estimate for the target population. Therefore, rather than relegating 
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considerations of external validity of the results to a thought exercise in the discussion of this 
manuscript, I applied a formal correction for non-random sampling into the study sample 
(inverse probability weights for sampling). This formal assessment of generalizability provides 
confidence in the generalizability of any research in the CNICS that uses mortality as an 
outcome. The assumptions required for using these methods are detailed further in section 7.1 of 
this document. 
I believe these results are unlikely to be to have been meaningfully affected by 
measurement and selection bias. CNICS relies on pharmacy or physician notes in the medical 
record to indicate initiation of ART drugs. ART is not accessible to patients outside the clinical 
setting, so the specificity of this measurement should be very high. Some patient records 
indicated very short courses of therapy, leading to uncertainty as to whether or not therapy had 
actually been initiated. Applying different windows of minimal ART use (0-30 days) to define 
ART initiation did not meaningfully change the results. I assumed that once patients initiated 
ART, they remained on ART. I could not assess ART discontinuation rates in the CNICS 
because discontinuation dates have not yet been constructed across the entire study period. 
However, in other studies, ART discontinuation was rare.22,23 Furthermore, using all-cause 
mortality as an endpoint reduces the probability of outcome measurement error because there is 
nearly complete ascertainment of outcomes. Finally, prior analyses have shown that, despite high 
rates of loss-to-clinic, the effect of loss-to-clinic on mortality is minimal in the CNICS and 
inverse probability of censoring weighting of persons who are retained in the clinic is sufficient 
to reconstruct the crude mortality curves.109  
When generalizing the estimate from CNICS to persons newly diagnosed with HIV in the 
US, I may not have controlled for all causes of selection into the sample and of the outcome. 
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CD4 cell count and viral load at baseline were associated with the risk of all-cause mortality, but 
neither were available in the national surveillance data for all persons at the time they were HIV-
diagnosed. Not all HIV-infected persons have laboratory tests drawn immediately proximate to 
their diagnosis, and not all states currently collect prognostic laboratory results through HIV 
surveillance. Furthermore, even if prognostic laboratory measurements were somehow available 
for all newly diagnosed persons (e.g., if prognostic laboratory values were measured on all blood 
samples used to confirm HIV diagnosis),  if  those  persons  don’t  immediately  enter  HIV  care,  the  
values of those measurements may worsen and not be comparable to the baseline CD4 cell 
counts and viral loads observed in CNICS patients at CNICS enrollment. Failing to account for 
differences in the distribution of CD4 cell count and viral load at baseline between the CNICS 
and target population may be a source of residual bias in the generalized effect estimate.110 
However, sensitivity analyses indicated that even modest shifts in the average CD4 or viral load 
of patients in the target population as compared to CNICS failed to appreciably alter the 
estimated effect of ART (Table 5.5). Treatment versions may differ between the CNICS and the 
target population as CNICS patients are all treated in academic medical centers, which may 
influence patient adherence and quality of care.111 There was a positive probability of inclusion 
in the CNICS in nearly all strata of covariates, owing to the diversity of the CNICS cohort, 
which was reflected in the stability of the inverse probability of sampling weights. Finally, 
generalizability may be threatened in the presence of interference;86 however, interference is 
likely negligible for this exposure-outcome relationship.   
In this study, I showed that ART reduced mortality in a cohort that is geographically and 
clinically representative of persons recently diagnosed with HIV in the US. The estimates 
obtained in the cohort and in the formal generalization to the target population of recently HIV-
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diagnosed persons in the US were similar. Furthermore, by including persons with prior AIDS 
diagnosis at baseline, and by excluding people with prior exposure to dual- or mono-therapy, the 
estimated effect is pertinent to current standards of clinical care. Although there was some 
heterogeneity in the effect of ART across sub-populations and differences in the distribution of 
those sub-populations between the CNICS and the target population, this heterogeneity did not 
change the overall estimate of the effect of ART among persons recently diagnosed with HIV in 
the US after appropriate weighting. 
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Table 5.1. Characteristics of persons enrolled in the Center for AIDS Research Network of 
Integrated Clinical Systems (CNICS) during 1998-2012, and persons diagnosed with HIV in the 
United States during 2009-2011 
 
CNICS Study Sample at 
Enrollment 
Recently HIV-
Diagnosed Persons in 
the United States, 2009-
2011 
Total N 12,457 128,945 
Sex   
   Male 10,265 (82) 100,819 (78) 
   Female 2,282 (18) 28,126 (22) 
Age    
   Median age (IQR) 38 (31, 45)  
   18-24 years 980 (8) 25,535 (20) 
   25-34 years 3,731 (30) 35,625 (28) 
   35-44 years 4,766 (38) 31,153 (24) 
   45-54 years 2,471 (20) 25,030 (19) 
   ≥55  years 599 (5) 11,602 (9) 
Race/ethnicity   
   White 5,539 (44) 36,635 (28) 
   Black 4,789 (38) 60,516 (47) 
   Hispanic 1,635 (13) 26,079 (20) 
   Other 584 (5) 5,715 (4) 
History of AIDS at baseline 2,343 (19) 32,896 (26) 
HIV risk category   
   History of injection drug use only 1,440 (12) 6,324 (5) 
   Male-to-male sexual contact only 6,606 (53) 77,802 (60) 
   Injection drug use and male-to-male  
      sexual contact 
903 (7) 4,105 (3) 
*Abbreviations: CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; 
AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; IQR, 
interquartile range.  
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Table 5.2. Characteristics associated with initiation of 3+ antiretroviral medications (ART), 
censoring, and CNICS enrollment for 12,547 HIV-positive patients receiving care at CNICS 
sites, 1998-2011 
 ART Initiation  Censoring  CNICS Enrollment 
 Hazard  
Ratio 
95% 
Confidence 
Interval 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
 Odds 
Ratio 
95% 
Confidence 
Interval 
Male sex 0.97 0.90, 1.04  1.19 1.10, 1.30  1.45 1.36, 1.54 
Age at CNICS enrollment         
18-24 years       0.27 0.26, 0.30 
25-34 years       0.71 0.68, 0.75 
35-44 years       1.00  
45-54 years       0.61 0.58, 0.65 
≥55  years       0.32 0.29, 0.35 
Race/ethnicity          
      White 1.00   1.00   1.00  
Black 0.88 0.83, 0.93  0.94 0.88, 1.01  0.55 0.53, 0.57 
Hispanic 0.86 0.80, 0.92  1.00 0.92, 1.09  0.41 0.38, 0.43 
Other 0.96 0.85, 1.07  1.04 0.91, 1.18  0.69 0.64, 0.72 
Calendar year of CNICS 
enrollment, per year 
1.08 0.07, 1.09  1.02 1.01, 1.03    
Prior AIDS diagnosis 1.19 1.11, 1.26  0.88 0.82, 0.95  0.59 0.57, 0.62 
Injection drug use 0.68 0.63, 0.73  0.96 0.88, 1.04  2.17 2.06, 2.30 
Male-to-male sexual 
contact 
1.11 1.05, 1.19  0.89 0.82, 0.96  0.68 0.64, 0.72 
Hepatitis C virus infection 0.93 0.86, 1.00  0.92 0.84, 1.00    
ART use NA   0.34 0.32, 0.37  NA  
*Abbreviations: ART, antiretroviral therapy; AIDS, acquired immunodeficiency syndrome; HIV, 
human immunodeficiency virus; CNICS, Center for AIDS Research Network of Integrated 
Clinical Systems 
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Table 5.3. Modification of the effect of 3+ antiretroviral medications (ART) on all-cause mortality for 12,547 HIV-positive 
patients receiving care at CNICS sites, 1998-2011 
Hazard Ratio  
(95% CI) 
0.33 (0.25, 0.43) 
 
0.35 (0.27, 0.45) 
0.41 (0.26, 0.64) 
 
1.77 (0.00, 1140.12) 
0.38 (0.21, 0.66) 
0.43 (0.32, 0.57) 
0.24 (0.16, 0.37) 
0.38 (0.18, 0.78) 
 
0.26 (0.18, 0.38) 
0.44 (0.33, 0.58) 
0.37 (0.19, 0.72) 
0.74 (0.35, 1.57) 
 
0.26 (0.21, 0.33) 
0.42 (0.26, 0.68) 
0.51 (0.26, 0.99) 
0.71 (0.37, 1.37) 
Risk Ratio  
(95% CI) 
0.37 (0.26, 0.53) 
 
0.49 (0.36, 0.67) 
0.41 (0.23, 0.71) 
 
1.79 (0.27, 12.03) 
0.31 (0.16, 0.58) 
0.60 (0.41, 0.87) 
0.35 (0.21, 0.59) 
0.63 (0.35, 1.14) 
 
0.32 (0.19, 0.53) 
0.56 (0.38, 0.82) 
0.38 (0.15, 0.92) 
0.50 (0.15, 1.62) 
 
0.37 (0.27, 0.52) 
0.43 (0.21, 0.89) 
0.44 (0.14, 1.32) 
0.64 (0.32, 1.28) 
Risk Difference, 
% (95% CI) 
-17.7 (-27.0, -8.4) 
 
-10.5 (-16.1, -4.8) 
-17.3 (-33.5, -1.1) 
 
1.2 (-7.0, 9.4) 
-15.3 (-27.4, -3.3) 
-7.2 (-13.2, -1.2) 
-29.0 (-48.8, -9.2) 
-12.3 (-30.0, 5.4) 
 
-17.3 (-28.9, -5.8) 
-11.3 (-20.4, -2.2) 
-10.1 (-21.8, 1.6) 
-11.4 (-33.8, 10.9) 
 
-29.3 (-43.4, -
15.2) -10.1 (-22.8, 2.5) 
-7.1 (-19.4, 5.1) 
-2.5 (-6.0, 1.0) 
ART 
Unexposed,  
5-year Mortality 
Risk, %  
28.3 (19.1, 37.5) 
 
20.6 (15.2, 26.0) 
29.1 (13.1, 45.1) 
 
1.5 (0.0, 9.4) 
22.1 (10.2, 34.0) 
18.1 (12.4, 23.8) 
44.7 (25.1, 64.2) 
33.5 (17.2, 49.8) 
 
25.5 (14.2, 36.9) 
25.7 (16.7, 34.6) 
16.2 (4.5, 27.7) 
22.9 (1.7, 44.1) 
 
46.5 (32.7, 60.4) 
17.7 (5.1, 30.2) 
12.6 (0.5, 24.7) 
6.9 (4.6, 9.2) 
ART  
Exposed,  
5-year Mortality 
Risk, % 
10.6 (9.3, 11.9) 
 
10.1 (8.7, 11.5) 
11.8 (9.7, 14.0) 
 
2.6 (0.7, 4.5) 
6.7 (5.3, 8.2) 
10.9 (8.5, 13.2) 
15.6 (12.3, 19.0) 
12.2 (15.1, 27.3) 
 
8.2 (6.6, 9.8) 
14.4 (11.9, 16.9) 
6.1 (4.3, 7.9) 
11.5 (4.9, 18.1) 
 
17.2 (15.6, 18.9) 
7.6 (5.6, 9.5) 
5.5 (2.0, 6.8) 
4.4 (2.0, 6.8) 
 
Overall 
Sex 
     Male 
     Female 
Age at CNICS start 
     18-24 years 
     25-34 years 
     35-44 years 
     45-54 years 
     ≥55  years 
Race/ethnicity 
     White 
     Black 
     Hispanic 
     Other 
Baseline CD4 count 
     ≤200  cells/mm3 
     201-350 cells/mm3 
     351-500 cells/mm3 
     >500 cells/mm3 
 
49 
 
Table 5.3. (Continued) Modification of the effect of 3+ antiretroviral medications (ART) on all-cause mortality for 12,547 
HIV-positive patients receiving care at CNICS sites, 1998-2011 
Hazard Ratio 
(95% CI) 
 
0.55 (0.31, 0.98) 
0.50 (0.35, 0.72) 
0.20 (0.15, 0.26) 
 
0.39 (0.30, 0.54) 
0.28 (0.20, 0.40) 
 
0.49 (0.34, 0.72) 
0.30 (0.23, 0.40) 
 
0.32 (0.23, 0.45) 
0.39 (0.29, 0.51) 
*Abbreviations: ART, antiretroviral therapy; AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency 
virus; CNICS, Center for AIDS Research Network of Integrated Clinical Systems; MSM, male-to-male sexual contact 
Risk Ratio  
(95% CI) 
 
0.49 (0.26, 0.90) 
0.40 (0.22, 0.73) 
0.35 (0.21, 0.51) 
 
0.48 (0.32, 0.70) 
0.36 (0.24, 0.54) 
 
0.53 (0.35, 0.81) 
0.35 (0.23, 0.53) 
 
0.47 (0.30, 0.72) 
0.47 (0.33, 0.66) 
Risk Difference, % 
(95% CI) 
 
-5.4 (-10.8, -0.1) 
-14.1 (-26.2, -2.1) 
-28.7 (-45.3, -12.1) 
 
-22.8 (-38.3, -7.3) 
-13.4 (-21.3, -5.5) 
 
-18.1 (-31.8, -4.4) 
-14.4 (-23.2, -5.7) 
 
-8.0 (-13.9, -2.0) 
-17.1 (-27.4, -6.7) 
ART 
Unexposed,  
5-year Mortality 
Risk, %  
 
10.6 (5.5, 15.7) 
23.7 (12.2, 35.3) 
42.5 (26.1, 58.9) 
 
47.5 (27.9, 59.1) 
20.9 (13.2, 28.7) 
 
38.5 (25.4, 51.6) 
22.3 (13.7, 30.9) 
 
15.0 (9.3, 20.7) 
32.1 (22.1, 42.1) 
ART  
Exposed,  
5-year Mortality 
Risk, % 
 
5.2 (3.2, 7.2) 
9.6 (7.8, 11.4) 
13.8 (12.1, 15.6) 
 
20.7 (17.9, 23.5) 
7.6 (6.4, 8.7) 
 
20.4 (15.6, 25.2) 
7.8 (7.0, 8.7) 
 
7.0 (5.6, 8.4) 
15.1 (12.7, 17.4) 
 
Baseline viral load 
     <10,000 copies/mL 
     10,000-99,999  
              copies/mL 
     ≥100,000  
copies/mL AIDS at baseline 
    Yes 
    No 
Injection drug use  
    Yes 
    No 
MSM 
    Yes 
    No 
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Table 5.4. Effect of 3+ antiretroviral medications (ART) on all-cause mortality for: 1) persons 
enrolled in the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) 
during 1998-2012; and 2) persons diagnosed with HIV in the United States during 2009-2011 
 5-year 
Mortality Risk, % 
(95% Confidence 
Interval) 
Risk Difference, % 
(95% Confidence 
Interval) 
Risk Ratio 
(95% Confidence 
Interval) 
Hazard Ratio 
(95% Confidence 
Interval) 
CNICS sample     
  Crude     
     No ART 12.1 (10.0, 14.3) 0. 1. 1. 
     ART 11.3 (10.4, 12.1) -0.9 (-3.2, 1.5) 0.93 (0.76, 1.13) 1.01 (0.87, 1.17) 
  Weighted     
     No ART 28.3 (19.1, 37.5) 0.  1. 1. 
     ART 10.6 (9.3, 11.9) -17.7 (-27.0, -8.4) 0.37 (0.26, 0.53) 0.33 (0.25, 0.43) 
     
HIV-diagnosed, 
United States 
    
     No ART 29.5 (18.2, 40.8) 0. 1. 1. 
     ART 10.4 (9.2, 11.6) -19.1 (-30.5, -7.8) 0.35 (0.23, 0.53) 0.32 (0.23, 0.45) 
*Abbreviations: ART, antiretroviral therapy  
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Table 5.5. Sensitivity analysis examining hazard ratios for 3+ antiretroviral medications (ART) 
on all-cause mortality among persons diagnosed with HIV in the United States during 2009-2011 
(target population) assuming different distributions of CD4 cell count and viral load in the target 
(unmeasured) as compared to the CNICS study sample 
CD4 Cell 
Count in 
Target is on 
Average… 
Viral Load in the Target is on Average… 
10,000 Lower Than the 
Sample for Patients with a 
Predicted Viral Load 
>100,000 
Equal to Sample 10,000 Higher Than the Sample 
200 cells/mL 
higher than 
the sample 
0.45 (0.28, 0.71) 0.38 (0.23, 0.63) 0.40 (0.25, 0.65) 
100 cells/mL 
higher than 
the sample 
0.40 (0.27, 0.60) 0.35 (0.24, 0.50) 0.35 (0.24, 0.53) 
50 cells/mL 
higher than 
the sample 
0.37 (0.25, 0.55) 0.35 (0.25, 0.49) 0.34 (0.23, 0.49) 
Equal to 
sample 0.35 (0.24, 0.52) 0.34 (0.24, 0.47) 0.32 (0.22, 0.46) 
50 cells/mL 
lower than 
the sample 
0.33 (0.23, 0.48) 0.32 (0.23, 0.45) 0.30 (0.21, 0.43) 
100 cells/mL 
lower than 
the sample 
0.31 (0.22, 0.45) 0.30 (0.21, 0.42) 0.29 (0.20, 0.41) 
200 cells/mL 
lower than 
the sample 
0.34 (0.23, 0.50) 0.33 (0.22, 0.50) 0.32 (0.21, 0.47) 
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Figure 5.1. 5-year all-cause mortality under two potential interventions: always treat versus never 
treat with 3+ antiretroviral medications (ART) among: 1) persons enrolled in the Center for 
AIDS Research Network of Integrated Clinical Systems (CNICS) during 1998-2012; and 2) 
persons diagnosed with HIV in the United States during 2009-2011  
 
  
53 
 
 
 
CHAPTER 6: RESULTS. TEN-YEAR SURVIVAL BY RACE/ETHNICITY AND SEX 
AMONG TREATED, HIV-INFECTED ADULTS IN THE UNITED STATES 
 
HIV/AIDS is a social malady as well as an infectious disease, with infection and 
morbidity most prevalent among vulnerable and underserved groups. Overcoming disparities in 
morbidity and mortality among people living with HIV is a principal tenet of the US National 
HIV/AIDS Strategy.112 Implementing strategies to reduce disparities, however, requires 
knowledge about whether disparities are arising as opposed to persisting across the continuum of 
HIV care. In this aim, I describe 10-year all-cause mortality after therapy initiation between 1998 
and 2011 by race, ethnicity and sex among a sample of adult patients in the US. I present 
standardized results to estimate disparities arising after therapy initiation, controlling for 
differences in pre-treatment health status. A detailed description of the methods is available in 
section 4.2 of this document. 
 
6.1.  Results 
The median age in the study sample was 40 years (interquartile range (IQR): 33, 46) and 
the median year of therapy initiation was 2006 (IQR: 2003, 2009). The median baseline CD4 
count and viral load were 238 cells/mm3 (IQR: 85, 385) and 4.7 log10 copies/ml (IQR: 3.9, 5.3), 
respectively (Table 6.1). Most patients (88%) were treatment-naïve, 27% had a prior AIDS-
defining condition, 18% had a history of injection drug use and 16% had a history of hepatitis C 
virus infection. The median time spent in the CNICS prior to initiation of therapy was 68 days 
(IQR: 21-371 days). The prevalence of a prior AIDS-defining condition at baseline was 22% 
54 
 
among white men, compared with 28% to 34% of persons in all other race/ethnicity and sex 
groups. Additionally, 30% of white women had a history of injection drug use, compared to only 
12% to 19% in all other race/ethnicity and sex groups, with a correspondingly high risk of HCV 
infection. 
  Patients were followed for a median of 4.7 years (IQR: 2.2, 8.2). During 51,121 person-
years of follow up, 1,224 of the 10,017 patients died. The overall crude 10-year mortality risk 
was 20.2% (95% CI: 19.2%, 21.3%) and the overall crude mortality rate was 2.39 deaths per 100 
person-years (95% CI: 2.26, 2.53). The crude 10-year mortality risk was 27.0% (95% CI: 24.6%, 
29.3%) among black men and 25.0% (95% CI: 21.6%, 28.4%) among black women. In contrast, 
the crude 10-year mortality risk was only 16.8% (95% CI: 15.1%, 18.5%) among white men and 
17.5% (95% CI: 12.9%, 22.1%) among white women. Among Hispanic men and women, the 
crude 10-year mortality risk was 12.5% (95% CI: 9.5%, 15.5%) and 12.0% (95% CI: 4.5%, 
19.4%), respectively (Figure 3.1).  
Black men and women experienced a standardized 10-year risk of mortality that was 
7.2% (95% CI: 4.3%, 10.1%) and 7.9% (95% CI: 3.9%, 12.0%) larger than white men. The 
standardized 10-year risk of mortality was 4.0% (95% CI: -8.5%, 0.4%) less among white 
women compared to white men. Among Hispanic men and women, the standardized 10-year risk 
of mortality was 3.2% (95% CI: -7.1%, 0.8%) and 7.1% (95% CI: -16.1%, 1.9%) less, 
respectively than the mortality risk among white men. Standardized risk ratios and hazard ratios 
exhibited a similar pattern (Table 6.2). Stratifying on CNICS site did not substantively change 
the results, but it slightly attenuated the estimated relative hazard of all-cause mortality for black 
men and women, and shifted the estimated relative hazard for white women and Hispanic men 
and women downwards, away from the null (Table 6.6).  
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 Mortality risk followed similar patterns by race/ethnicity, regardless of sex. The 
standardized 10-year all-cause mortality risk was 8.2% larger for black patients (95% CI: 5.6%, 
10.8%) and 2.7% smaller than for Hispanic patients (95% CI: -6.6%, 1.1%) compared to white 
patients. Mortality risk also followed similar patterns by sex, regardless of race/ethnicity. The 
standardized 10-year all-cause mortality risk for women was 2.2% larger than men (95% CI: -
0.7%, 5.2%).  
Disparities in survival did not change significantly over the study period (p-values for 
interaction between time period and race/ethnicity and sex were 0.14 when the time period was 
divided into pre- and post-2002, 0.66 for 2004, 0.75 for 2006, and 0.43 for 2008). 
The mortality rate ratio comparing black men with white men in the CNICS was higher 
than the mortality rate ratio comparing black men with white men in the US general population. 
The mortality rate ratio comparing black women with white men vastly exceeds the mortality 
rate ratio comparing black women with white men in the US general population. The relative rate 
of mortality for Hispanic men and women compared with white men in the CNICS was higher 
and closer to the null than the relative rate of mortality for Hispanic men and women with white 
men in the US general population (Table 6.3).  
Overall, 66.6% (95% CI: 65.7%, 67.5%) of patients were virally suppressed around 1 
year after ART initiation and 75.9% (95% CI: 75.1%, 76.8%) of patients were retained in care at 
2 years after ART initiation. There were substantial differences in viral suppression at 1 year 
post-ART initiation that may point to mechanisms for disparities in survival. Only 59.5% (95% 
CI: 58.0%, 61.1%) of black patients were virally suppressed at 1 year after ART initiation, 
compared to 70.9% (95% CI: 69.6%, 72.2%) of white patients and 72.0% (95% CI: 69.7%, 
74.3%) of Hispanic patients. Patterns were similar in men and women. There were only minor, 
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non-significant differences in retention in care at 2 years post-ART initiation by race/ethnicity 
and sex. Weighting the data to standardize on baseline covariates had little impact on the results 
(Table 6.4). 
 
6.2.  Discussion 
 There was a markedly higher risk of death from any cause among black men and women 
compared to other race/ethnicity groups in the CNICS cohort following antiretroviral therapy 
initiation. Survival by race/ethnicity and sex varies substantially in the general US population 
due to differences in the prevalence of non-HIV-related conditions like diabetes, hypertension, 
kidney disease and violence, for example.113 As a result, by estimating the risk of all-cause 
mortality, rather than focusing specifically on AIDS-defining illness-associated mortality, I have 
likely captured differences in the risk of non-AIDS-related causes of death. However, the 
disparities seen in the CNICS comparing mortality among black persons with white men exceeds 
the disparities in the US general population comparing black person with white men, especially 
for black women.103 Standardized estimates control for disparities in HIV-related health status 
prior to therapy initiation;13-15,114 the overall lower survival among HIV-infected black persons is 
only compounded by disparities after therapy initiation as is evident in contrasts of crude 
mortality risks. Although a thorough mediation analysis is beyond the scope of this study, I 
observed lower viral suppression at 1-year after therapy initiation among black patients. Other 
studies have documented greater loss-to-follow-up, more missed visits, and poorer therapy 
adherence among black patients,59,115 which may explain some of the survival disparities 
observed in this cohort.  
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The 10-year mortality risk in the CNICS cohort was slightly lower for Hispanic patients 
compared to non-Hispanic white patients. Although Hispanic men and women in the CNICS 
tend to experience lower mortality rates than white men, the magnitude of rate ratio is less than 
the rate ratio comparing Hispanic men and women to white men in the general population.103 The 
survival advantage that Hispanic persons in the general population is still incompletely 
understood.116 As such, it is difficult to interpret the relative risk of mortality for Hispanics in the 
CNICS as a survival advantage (since they do better than their white male counterparts) or as a 
disadvantage (since they do not do as much better as their HIV-uninfected counterparts). This 
study is one of a few with sufficient size to estimate survival among Hispanic ART initiators. In 
some settings, Hispanic patients appear to have poorer retention in care117 and lower probability 
achieving viral suppression33 as compared to white patients. However, other studies have found 
no evidence of ethnic disparities for similar outcomes,118 or even a lower hazard of AIDS 
incidence or death for Hispanic patients with equal access to care.17 The discrepant results may 
be due to many factors including: exposure misclassification associated with self-reported 
ethnicity; geographical differences in structural discrimination and access to care experienced by 
Hispanics; or the heterogeneity of the Hispanic community, owing to different countries of 
origin, residency statuses and generations since immigration to the US, among other things.119  
Mortality risk observed in the CNICS was similar or slightly higher among women than 
among men after accounting for differences in baseline covariates (including race/ethnicity). In 
other cohorts, mortality rates were higher among men than among women120 or there were no 
differences in survival between men and women.51 While women have been reported to be more 
likely than men to be retained in care,38,118 we observed similar prevalence of gaps in care by two 
years after therapy initiation. Notably, we found that while black women had poorer survival 
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than black males, white and Hispanic women generally had better survival than white and 
Hispanic men, respectively. Few previous studies that have examined survival by sex have 
simultaneously stratified by race/ethnicity, despite evidence of heterogeneity of HIV death rates 
within strata of both race/ethnicity and sex.43,121 
I estimated all-cause mortality following therapy initiation by race, ethnicity, and sex, 
standardized to the total cohort at therapy initiation to control for baseline differences in health 
status. I view race, ethnicity, and sex as markers for unmeasured factors, such as environment, 
income, social status, social capital, discrimination, structural violence and other phenomena, 
which may partially or completely explain the demographic disparities I observed.122 I did not 
standardize for these factors because my purpose was not to explain demographic disparities, but 
rather to document their presence and estimate their magnitude.   
Measurement bias is unlikely to explain the strong survival disparities observed in this 
study. Sex, race, ethnicity and death are likely measured with negligible error. Race and ethnicity 
are collected differently across sites, but are typically based on self-report and are classified in 
CNICS using Health Resources and Services Administration standards. Patients were classified 
as having a single race, which may have oversimplified race in multiracial patients, although the 
proportion of the US population that is multiracial is relatively low (2.9%, according to the 2010 
Census).123 Selection bias is also unlikely to explain the observed results, as the primary 
outcome, mortality, was ascertained via a national database; patients were not lost to follow-up 
because administrative censoring was unnecessary (e.g., after prolonged gap in labs or visits). 
Additionally, nearly all members of the eligible cohort were included in these analyses (only 8% 
of otherwise eligible subjects were excluded due to missing data).  
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These findings may or may not generalize to the US population.8 The CNICS cohort has 
proportionately more white patients, fewer young adults, more men and more injection drug 
users than are HIV-diagnosed and living in the US. Furthermore, CNICS clinics are all 
associated with academic medical centers, which may not reflect the HIV care provided in non-
academic settings. However, the geographic distribution of study sites more closely resembles 
the US population than studies conducted in any single clinic. 
A subsequent investigation into the causes of death would be invaluable to tease out the 
relative contributions of AIDS-related and non-AIDS-related mortality to the disparity described 
in this study. At this time, however, cause of death data is not available for all CNICS patients, 
and the data that is available is generally from the underlying cause of death on the death 
certificate, which has been shown to have poor specificity.124,125  
In summary, I identified elevated and meaningful differences in mortality among black 
men and women following combination antiretroviral therapy initiation in a large, 
demographically and geographically diverse cohort. These results serve as a call to action to 
identify modifiable factors that contribute to these observed differences, so that efficacious 
interventions may be developed and implemented so that the goal of the National HIV/AIDS 
Strategy112 to overcome health disparities becomes a reality.  
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Table 6.1. Characteristics at antiretroviral therapy initiation, 10,017 HIV-infected adults, 1998-2011a 
Hispanic 
women 
n = 169 
 
39 (30, 47) 
2007  
(2004, 2009) 
217 (91, 324) 
4.5 (3.4, 5.0) 
151 (89%) 
51 (30%) 
31 (18%) 
36 (21%) 
Abbreviations: AIDS, acquired immunodeficiency syndrome 
a Median (quartiles) unless noted otherwise 
 
Hispanic men 
n = 1,252 
 
37 (31, 43) 
2007  
(2004, 2010) 
226  
(77, 364) 
4.7 (3.9, 5.3) 
1,122 (90%) 
364 (29%) 
144 (12%) 
137 (11%) 
White 
women 
n=457 
 
41 (32, 46) 
2005 
 (2003, 2009) 
256  
(114, 407) 
4.7 (3.8, 5.3) 
397 (87%) 
127 (28%) 
139 (30%) 
133 (29%) 
White men 
n=4,228 
 
40 (34, 46) 
2007  
(2003, 2009) 
276  
(126, 428) 
4.7 (3.9, 5.3) 
3,724 (88%) 
912 (22%) 
715 (17%) 
528 (12%) 
Black women 
n=1,232 
 
40 (33, 47) 
2005  
(2002, 2008) 
210 (64, 348) 
4.7 (3.9, 5.3) 
1,030 (84%) 
415 (34%) 
224 (18%) 
222 (18%) 
Black men 
n=2,679 
 
40 (33, 47) 
2006  
(2002, 2009) 
196 (44, 343) 
4.7 (4.1, 5.3) 
2,364 (88%) 
866 (32%) 
505 (19%) 
516 (19%) 
 
 
 
 
 
 
 
 
 
 
 
Overall 
n = 10,017 
 
40 (33, 46) 
2006  
(2003, 2009) 
238 
 (85, 385) 
4.7 (3.9, 5.3) 
8,787 (88%) 
2,735 (27%) 
1,758 (18%) 
1,572 (16%) 
  
 
Age, years 
Calendar year 
CD4 count, 
cells/mm3 
Viral load, 
log10 
copies/ml 
Therapy naïve, 
n (%) 
AIDS, n (%) 
Injection drug 
use, n (%) 
Hepatitis C 
viral infection, 
n (%) 
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Table 6.2. Standardizeda 10-year mortality risk differences and hazard ratios and by race/ethnicity and sex, 10,017 HIV-
infected adults, 1998-2011 
 Standardized 
Hazard Ratio 
(95% CI) 
- 
 
1.57 (1.32, 1.87) 
1.53 (1.33, 1.76) 
1 
0.82 (0.64, 1.05) 
0.85 (0.61, 1.19) 
0.68 (0.37, 1.23) 
 
1 
1.29 (1.12, 1.49) 
0.75 (0.59, 0.96) 
 
1 
0.95 (0.82, 1.10) 
Abbreviations: CI, confidence interval; No., number 
a Standardized for calendar date of therapy initiation, age at therapy initiation, CD4 cell count (cells/mm3) and HIV-1 
RNA plasma concentration (viral load) (log10 copies/ml) most proximate to therapy initiation measured between 6 months 
prior to 14 days after therapy initiation, antiretroviral therapy naivety (i.e., no evidence of prior exposure to mono or dual 
therapy), prior AIDS diagnosis, history of injection drug use, and history of hepatitis C virus infection; additionally, 
race/ethnicity risk was standardized for sex and sex risk was standardized for race/ethnicity. 
Risk ratio (95% 
CI) 
- 
 
1.44 (1.21, 1.72) 
1.40 (1.23, 1.61) 
1 
0.82 (0.63, 1.08) 
0.77 (0.57, 1.05) 
0.61 (0.26, 1.42) 
 
1 
1.48 (1.30, 1.67) 
0.84 (0.65, 1.09) 
 
1 
1.11 (0.97, 1.28) 
Risk difference, 
% (95% CI) 
- 
 
7.9 (3.9, 12.0) 
7.2 (4.3, 10.1) 
0 
-3.2 (-7.1, 0.8) 
-4.0 (-8.5, 0.4) 
-7.1 (-16.1, 1.9) 
 
0 
8.2 (5.6, 10.8) 
-2.7 (-6.6, 1.1) 
 
0 
2.2 (-0.7, 5.2) 
10-year 
mortality 
risk, % 
20.2 
 
25.8 
25.2 
18 
14.8 
13.9 
10.8 
 
17.2 
25.4 
14.5 
 
19.8 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crude 
10-year 
mortality 
risk, % 
20.2 
 
25 
27 
16.8 
12.5 
17.5 
12 
 
16.9 
26.3 
12.5 
 
19.7 
22.2 
No. 
Person-
years 
51,121.1 
 
6,730.0 
13,338.4 
21,792.3 
5,924.6 
2,482.0 
853.9 
 
24,274.3 
20,068.4 
6,778.5 
 
41,055.3 
10,065.8 
No. 
Deaths 
1,224 
 
207 
458 
405 
86 
53 
15 
 
458 
665 
101 
 
949 
275 
 
 
Overall 
Race/ethnicity/sex 
     Black women 
     Black men 
     White men 
     Hispanic men 
     White women 
     Hispanic women 
Race/ethnicity 
     White 
     Black 
     Hispanic 
Sex 
     Men 
     Women 
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Table 6.3. Crude mortality rate ratios for 10,017 HIV-infected adults in the CNICS, 1998-2011, 
and age- and calendar time-standardized mortality rates in the US general population based on 
vital statistics data, 1999-2011 
 CNICS, 1998-2011   US population, 1999-2011 
Race/ethnicity/sex 
No. 
Deaths 
No. 
Person-
years 
Mortality rate 
per 10,000 
person-years 
Rate 
Ratio  
Standardized 
mortality rate* 
Rate 
Ratio 
     Black women 207 6,730.0 307.6 1.66  45.7 1.05 
     Black men 458 13,338.4 343.4 1.85  73.9 1.70 
     White men 405 21,792.3 185.8 1.00  43.6 1.00 
     Hispanic men 86 5,924.6 145.2 0.78  27.0 0.62 
     White women 53 2,482.0 213.5 1.15  25.9 0.59 
     Hispanic women 15 853.9 175.7 0.95  18.5 0.42 
*Directly standardized to match the age group and calendar time distribution of the CNICS data  
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Table 6.4. Crude and standardizeda probabilities of retention in care at 2 years post-ART initiation and viral suppression at 1 
year post-ART initiation, by race/ethnicity and sex, 10,017 HIV-infected adults, 1998-2011 
Standardized 
Viral suppression at ~1 
year after ART 
initiation, % (95% CI) 
 
  
57.7 (54.9, 60.5) 
60.5 (58.7, 62.4) 
71.7 (70.3, 73.1) 
72.3 (69.9, 74.8) 
64.3 (59.9, 68.9) 
65.3 (58.0, 72.5) 
  
70.2 (68.9, 71.5) 
59.8 (58.2, 61.3) 
71.5 (69.2, 73.8) 
 
68.1 (67.1, 69.1) 
60.0 (57.8, 62.2) 
*  Retention  in  care  defined  as  no  gaps  in  laboratory  monitoring  of  ≥1  year 
a Standardized for calendar date of therapy initiation, age at therapy initiation, CD4 cell count (cells/mm3) and HIV-1 RNA 
plasma concentration (viral load) (log10 copies/ml) most proximate to therapy initiation measured between 6 months prior to 14 
days after therapy initiation, antiretroviral therapy naivety (i.e., no evidence of prior exposure to mono or dual therapy), prior 
AIDS diagnosis, history of injection drug use, and history of hepatitis C virus infection; additionally, race/ethnicity risk was 
standardized for sex and sex risk was standardized for race/ethnicity. 
Retention in care 2 years 
after ART initiation, % 
(95% CI) 
 
  
76.0 (73.6, 78.4) 
75.3 (73.6, 76.9) 
76.2 (74.9, 77.5) 
77.0 (74.7, 79.4) 
75.2 (71.3, 79.2) 
76.9 (70.5, 83.4) 
  
75.8 (74.6, 77.1) 
75.3 (74.0, 76.7) 
76.9 (74.7, 79.1) 
 
76.1 (75.1, 77.0) 
75.2 (73.2, 77.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crude 
Viral suppression at ~1 
year after ART 
initiation, % (95% CI) 
66.6 (65.7, 67.5) 
  
57.8 (55.0, 60.6) 
60.3 (58.4, 62.2) 
72.0 (70.6, 73.3) 
73.1 (70.6, 75.5) 
61.3 (56.8, 65.7) 
63.9 (56.2, 71.1) 
  
70.9 (69.6, 72.2) 
59.5 (58.0, 61.1) 
72.0 (69.7, 74.3) 
 
68.3 (67.3, 69.3) 
59.2 (56.9, 61.5) 
Retention in care 2 
years after ART 
initiation, % (95% CI) 
75.9 (75.1, 76.8) 
  
76.2 (73.8, 78.6) 
75.1 (73.5, 76.7) 
76.4 (75.1, 77.7) 
76.2 (73.8, 78.6) 
74.0 (69.9, 78.0) 
78.1 (71.9, 84.3) 
  
76.2 (75.0, 77.4) 
75.5 (74.1, 76.8) 
76.4 (74.2, 78.6) 
 
76.0 (75.0, 76.9) 
75.8 (73.9, 77.8) 
 
 
Overall 
 Race/ethnicity/sex 
     Black women 
     Black men 
     White men 
     Hispanic men 
     White women 
     Hispanic women 
 Race/ethnicity 
     White 
     Black 
     Hispanic 
Sex 
     Men 
     Women 
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Table 6.5. Characteristics at antiretroviral therapy initiation, 10,017 HIV-infected adults, 1998-2011a 
Female 
n=1,858 
40 (33, 47) 
2005  
(2002, 2008) 
221 (78, 361) 
4.7 (3.9, 5.2) 
1,578 (85%) 
593 (32%) 
394 (21%) 
391 (21%) 
Abbreviations: AIDS, acquired immunodeficiency syndrome 
a Median (quartiles) unless noted otherwise 
Male 
n=8,159 
40 (33, 46) 
2006  
(2003, 2009) 
242 (87, 391) 
4.8 (4.0, 5.3) 
7,209 (88%) 
2,142 (26%) 
1,364 (17%) 
1,181 (15%) 
 
 
 
 
 
 
 
 
 
 
Hispanic 
n=1,421 
37 (31, 44) 
2007  
(2004, 2010) 
226 (78, 362) 
4.7 (3.9, 5.3) 
1,273 (90%) 
415 (29%) 
175 (12%) 
173 (12%) 
Black 
n=3,911 
40 (33, 47) 
2006  
(2002, 2009) 
199 (51, 344) 
4.7 (4.0, 5.3) 
3,394 (87%) 
1,281 (33%) 
729 (19%) 
738 (19%) 
White 
n=4,685 
40 (34, 46) 
2006  
(2003, 2009) 
271 (124, 426) 
4.7 (3.9, 5.3) 
4,120 (88%) 
1,039 (22%) 
854 (18%) 
661 (14%) 
 
 
 
 
 
 
 
 
 
 
Overall 
n = 10,017 
40 (33, 46) 
2006  
(2003, 2009) 
238 (85, 385) 
4.7 (4.0, 5.3) 
8,787 (88%) 
2,735 (27%) 
1,758 (18%) 
1,572 (16%) 
 
 
Age, years 
Calendar year 
CD4 count, cells/mm3 
Viral load, log10 
copies/ml 
Therapy naïve, % 
AIDS, % 
Injection drug use, % 
Hepatitis C viral 
infection, % 
65 
  
Table 6.6. Sensitivity analysis, estimates of the relative hazard of all-cause mortality by race/ethnicity and sex, unstratified 
and stratified on CNICS site, 10,017 HIV-infected adults, 1998-2011 
Standardized, 
stratified by CNICS 
site (95% CI) 
 
1.18 (0.97, 1.43) 
1.24 (1.07, 1.45) 
1 
0.74 (0.57, 0.96) 
0.72 (0.51, 1.01) 
0.59 (0.32, 1.09) 
Abbreviations: CI, confidence interval; No., number 
a Standardized for age at therapy initiation, calendar year of therapy initiation, therapy naivety, and prior diagnosis of any 
AIDS-defining condition at therapy initiation 
Standardized, 
unstratified by 
CNICS site (95% CI) 
 
1.57 (1.32, 1.87) 
1.53 (1.33, 1.76) 
1 
0.82 (0.64, 1.05) 
0.85 (0.61, 1.19) 
0.68 (0.37, 1.23) 
Crude Hazard 
Ratio  
(95% CI) 
 
1.66 (1.41, 1.97) 
1.84 (1.61, 2.11) 
1 
0.78 (0.61, 0.98) 
1.15 (0.87, 1.54) 
0.94 (0.56, 1.59) 
 
 
 
 
 
 
 
 
10-year 
mortality 
risk, % 
 
25 
27 
16.8 
12.5 
17.5 
12 
No. 
Person-
years 
 
6,730.0 
13,338.4 
21,792.3 
5,924.6 
2,482.0 
853.9 
No. 
Deaths 
 
207 
458 
405 
86 
53 
15 
 
Race/ethnicity/sex 
     Black women 
     Black men 
     White men 
     Hispanic men 
     White women 
     Hispanic women 
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Figure 6.1. Crude all-cause mortality by years from therapy initiation, race/ethnicity and sex, 
10,017 HIV-infected adults, 1998-2011 
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Figure 6.2. Cumulative all-cause mortality standardizeda to total study sample by years from 
therapy initiation, race/ethnicity and sex, 10,017 HIV-infected adults, 1998-2011 
 
 
 
a Standardized by baseline covariates: age at therapy initiation, CD4 count and viral load, all 
modeled with restricted quadratic splines (with 4 knots located at the 5th, 35th, 65th and 95th 
percentiles), antiretroviral therapy naivety, prior diagnosis of any AIDS-defining condition at 
therapy initiation, injection drug use, and history of hepatitis C virus infection 
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Figure 6.3. Cumulative all-cause mortality standardizeda to the total study sample by years from 
therapy initiation and a) race/ethnicity or b) sex, 10,017 HIV-infected adults, 1998-2011 
 
a)  b) 
 
  
 
a Standardized by baseline covariates: sex (a) or race (b), age at therapy initiation, CD4 count 
and viral load, all modeled with restricted quadratic splines (with 4 knots located at the 5th, 35th, 
65th and 95th percentiles), antiretroviral therapy naivety, prior diagnosis of any AIDS-defining 
condition at therapy initiation, injection drug use, and history of hepatitis C virus infection 
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Figure 6.4. Log of the cumulative hazard of all-cause mortality standardizeda to the total study 
sample by years from therapy initiation, race/ethnicity and sex, 10,017 HIV-infected adults, 
1998-2011 
 
 
a Standardized by baseline covariates: age at therapy initiation, CD4 count and viral load , all 
modeled with restricted quadratic splines (with 4 knots located at the 5th, 35th, 65th and 95th 
percentiles), antiretroviral therapy naivety, prior diagnosis of any AIDS-defining condition at 
therapy initiation, injection drug use, history of hepatitis C virus infection and study site 
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CHAPTER 7: DISCUSSION 
 
7.1.  Generalizability of Effects 
Great care is typically taken in epidemiology and public health to study the internal 
validity of effect estimates, in particular the potentially biasing effects of measurement, 
confounding and selection. However, the external validity of effect estimates has been 
understudied and has important implications for health policy and planning. Interventions based 
on internally valid studies may have unexpected outcomes if those study results are not 
generalizable to the target population.126 The ideal study to estimate the effect of ART on 
mortality among recently HIV-diagnosed persons in the US would be conducted in a random 
sample from that population, with subsequent randomized treatment assignment. Randomized 
treatment assignment is not ethical in this instance, given the documented benefits of ART, 108 
and furthermore, accrual of follow-up time required for a prospective study would delay 
implementation of any intervention thought to be beneficial.  
The identifying assumptions necessary to conclude that an estimated effect is internally 
valid include: 1) conditional exchangeability between treatment arms (no unmeasured causes of 
both the exposure and the outcome);83 2) positive probability of treatment within every level of 
covariates (positivity);84 3) treatment variation irrelevance;85 4) no interference (when one 
person’s  outcome  is  affected  by  another’s  exposure);86 5) no measurement error;87 and 6) correct 
models specification. These assumptions have been well described.79,83,88 The generalizability 
assumptions necessary to conclude that an estimated effect is externally valid parallel the 
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identifying assumptions for internal validity: 1) conditional exchangeability between the selected 
and those not selected into the sample (no unmeasured causes of both selection into the sample 
and the outcome); 2) positive probability of being included in the study sample within every 
level of covariates (positivity); 3) treatment variation irrelevance or similar versions of treatment 
in the sample and the target;6 4) no interference or similar patterns of interference in the sample 
and the target;6,86 5) no measurement error; and 6) correct models specification.5,89,90 Under these 
assumptions, weighting creates a pseudo-population in which the exposure is independent of 
measured confounders, censoring is independent of exposure and measured confounders, and the 
distribution of effect-modifiers matches that in the target population. 
 In this dissertation, I demonstrated one method for formally assessing generalizability. 
There are many potential future directions for research into the generalizability of effects. 
Specifically, how much of a departure from homogeneity of subgroup effects is tolerable before 
we need to be concerned about the generalizability of the effect estimate? How vulnerable is the 
inverse probability weighted estimator for generalizability to the choice of N, the size of the 
hypothetical target population from which the study sample and the cohort sample used to 
describe the target are sampled? Is there another estimator that avoids the need for hypothetical 
N altogether? Furthermore, it may be more useful to contrast the expected 5-year mortality under 
more realistic interventions, such treat 90% of people immediately following diagnosis versus 
allow treatment uptake to follow its natural course in the cohort. Such contrasts are possible 
using the parametric g-formula.127 Using the parametric g-formula to accommodate 
generalizability may be a simple extension in which the datasets for the Monte Carlo simulation 
are drawn to reflect the baseline characteristics of the target population rather than of the study 
sample. Furthermore, the parametric g-formula estimator may improve the precision of estimates 
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over an inverse probability weighted estimator. However, this extension has not yet been 
evaluated. Finally, while this dissertation has demonstrated (under certain assumptions) the 
generalizability of the effect of ART on mortality measured in the CNICS to persons recently 
diagnosed with HIV in the US, there is still a need to test some of those assumptions or to 
evaluate the generalizability of other effects estimated in the CNICS.   
 
7.2.   Disparities 
The research question in Specific Aim 2 was descriptive (estimating association) rather than 
etiologic (estimating causal effects). While I could not identify the causes of disparities, I did 
document that disparities persist beyond initiation of ART, and are not entirely explained by HIV 
disease status at ART initiation. By restricting the investigation to persons who had initiated 
ART I hoped to identify focus areas for future investigation into the etiology of disparities. It is 
possible that the observed disparities may not be HIV-related at all. Survival by race/ethnicity 
and sex varies substantially in the general US population due to differences in the prevalence of 
non-HIV-related conditions like diabetes, hypertension, kidney disease and violence, for 
example.113 However, when contrasting inequalities in mortality among the general population 
and the HIV-positive ART initiators, the inequalities are greater for black HIV-positive ART 
initiators. Furthermore, the survival benefits seen among Hispanic persons and white women in 
the general population are not as strong among HIV-positive ART initiators (Table 7.1). The 
CNICS has recently begun collecting data on Patient Reported Outcomes (PRO) using self-
administered surveys. The richness of the data available in the PROs may be a fantastic resource 
for future studies into modifiable risk factors for mortality that may be targeted to reduce 
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disparities. Finally, it is relatively easy to nest studies in the CNICS to test the effect of 
interventions aimed at reducing disparities.  
 
Table 7.1. Death rates among the general population and among HIV-positive ART initiators by 
race/ethnicity and sex 
 Death rates in the general 
population, age 35-44 
(2011):20 
 HIV-positive ART initiators in the 
CNICS 
 Death Rate* Rate ratio  Death Rate* Hazard ratio 
Black women 208.900 0.93  3,075.8 1.57 
Black men 322.200 1.44  3,443.7 1.53 
White men  223.700 1.  1,858.5 1. 
Hispanic men 141.800 0.63  1,451.6 0.82 
White women 136.200 0.61  2,135.4 0.85 
Hispanic women 74.100 0.33  1,756.6 0.68 
*per 100,000 person-years 
 
There are numerous potential criticisms of health disparities research regarding the 
interpretation of the coefficient for the race/ethnicity/sex covariate in a regression model.128 
When considered from the potential outcomes framework, race, ethnicity and sex are 
problematic exposures as they are not manipulable, and so one cannot imagine any intervention 
that might produce a potential outcome other than the factual outcome consistent with the 
race/ethnicity/sex the person was. In a crude model, the coefficient on the race/ethnicity/sex 
covariate could be interpreted as a simple description of an inequality in outcomes across groups 
defined  by  race/ethnicity/sex.  The  ‘effect’  of  race/ethnicity/sex  is  poorly  defined  however, even 
ignoring the aforementioned problem of imagining an intervention on race/ethnicity/sex. One 
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could  imagine  asking  the  questions,  “What  is  the  effect  of  race-based  discrimination?”  “What  is  
the  effect  of  historical  racism?”  “What  is  the  effect  of gender-based  differences  in  income?”  or  
“What  is  the  effect  of  genetics  more  commonly  associated  with  one  ethnic  group  than  another?”  
Questions that might follow from the Specific Aim 2 of  this  dissertation  include,  “How  much  of  
the inequality in outcomes across groups defined by race/ethnicity/sex could be removed by 
earlier  HIV  diagnosis,  better  retention,  or  immediate  treatment  following  diagnosis?”   
 
7.3.   Conclusions 
The overall goal of this dissertation was to improve understanding of the potential 
population level impact of HIV treatment in the era of test-and-treat. Certainly, the effectiveness 
of HIV treatment-as-prevention129 and the additional individual health benefits that come from 
initiation of ART earlier in the course of illness provide compelling evidence to endorse the test-
and-treat strategy.130,131 However, a more detailed understanding of the effects of the strategy, 
specific to the population in which it will be implemented, is needed to plan appropriately and 
budget adequately to provide treatment for people over the additional years of life that they can 
expect from early treatment. In this dissertation, I estimated that immediately treating persons 
newly diagnosed with HIV in the US from 2009-2011 would reduce the 5-year risk of mortality 
in this group by two-thirds from nearly 30% if treatment were delayed, to 10%, which would 
translate to an extra 24,628 persons alive at 5 years post-diagnosis.  
The magnitude of the survival benefits of ART among recently HIV-diagnosed persons in 
the US were similar to those seen in the CNICS. Because it was not logistically or financially 
feasible to randomly sample from the target population that was of interest (i.e., persons recently 
diagnosed with HIV in the US), I conducted the main analysis in the CNICS. CNICS patients’ 
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characteristics were not identical to the characteristics of persons in the target population and we 
do not, as of yet, have a good understanding of the degree to which non-representativeness and 
non-significant departures from effect homogeneity across multiple subgroups interact to 
produce changes in the final standardized estimate for the target population. This dissertation 
therefore used a formal correction for non-random sampling into the study sample (inverse 
probability of sampling weights). This formal assessment of generalizability provides confidence 
in the generalizability of any research in the CNICS that uses mortality as an outcome. Further 
work is needed to quantify the vulnerabilities of results from studies conducted in samples that 
are not representative of the target population to which interventions will ultimately be applied. 
In the meantime, cohorts that are not representative samples can bolster claims of external 
validity by applying inverse probability of sampling weights to their final results. If the joint 
distribution of the characteristics of the target population is unknown, sensitivity analyses can be 
undertaken using multiple plausible distributions.  
Finally, reducing health disparities is a primary goals of the National HIV/AIDS 
Strategy.112 Documenting and quantifying disparities in survival is a key first step towards 
reducing them. In Specific Aim 1, by restricting the investigation to persons who have initiated 
ART, this study demonstrated that disparities in survival persist and arise anew as persons move 
through the HIV treatment cascade. Answering this question is important for deciding where to 
target research and interventions to mitigate disparities.  
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APPENDIX A. AIDS-DEFINING CONDITIONS (FOR PERSONS ≥13 YEARS OF AGE) 
 
 Candidiasis of bronchi, trachea, or lungs 
 Candidiasis of esophagus* 
 Cervical cancer, invasive 
 Coccidioidomycosis, disseminated or extrapulmonary 
 Cryptosporidiosis,  chronic  intestinal  (>1  month’s  duration) 
 Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month 
 Cytomegalovirus retinitis (with loss of vision)* 
 Encephalopathy, HIV-related 
 Herpes  simplex:  chronic  ulcers  (>1  month’s  duration)  or  bronchitis,  pneumonitis,  or  
esophagitis (onset at age >1 month) 
 Histoplasmosis, disseminated or extrapulmonary 
 Isosporiasis,  chronic  intestinal  (>1  month’s  duration) 
 Kaposi sarcoma* 
 Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex* 
 Lymphoma, Burkitt (or equivalent term) 
 Lymphoma, immunoblastic (or equivalent term) 
 Lymphoma, primary, of brain 
 Mycobacterium avium complex or Mycobacterium kansasii, disseminated* or 
extrapulmonary* 
 Mycobacterium tuberculosis of any site, pulmonary,* disseminated,* or extrapulmonary* 
 Mycobacterium, other species or unidentified species, disseminated* or extrapulmonary* 
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 Pneumocystis jerovecii pneumonia* 
 Pneumonia, recurrent* 
 Progressive multifocal leukoencephalopathy  
 Salmonella septicemia, recurrent 
 Toxoplasmosis of brain, onset at age >1 month* 
 Wasting syndrome attributed to HIV 
 
*Condition that might be diagnosed presumptively 
Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm  
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APPENDIX B. POWER CALCULATION USING EXPECTED DATA APPROACH 
 
I used the expected data approach to calculate power for Specific Aims 1 and 2. I 
generated data for the outcome of the study under a range of possibilities for the baseline rate 
and rate ratio (Specific Aim 1) or the baseline risk and the risk difference (Specific Aim 2) for 
each comparison of interest, then used that generated data to back-calculate power for each 
scenario.  
In Specific Aim 1, over 5 years of follow up, there were 918 deaths among 12,457 
patients in the study sample, and approximately 32% of the person-time was exposed to ART. I 
calculated the standard error for the risk ratio using the formula:  
𝑆𝐸(𝑟𝑎𝑡𝑒  𝑟𝑎𝑡𝑖𝑜) = ඨ
1
𝑎 +
1
𝑏 
Where 𝑎 is the number of exposed events (assumed to be 0.32*918) and 𝑏 is the number of 
unexposed events. I further assumed an expected hazard ratio of 0.5.  
In Specific Aim 2, I started with the number of subjects in each stratum of my exposure 
and calculated the expected number of events over 10 years, assuming a 10-year risk of 10%, 
15%, and 20% in the referent group (white or male), and a risk differences ranging from -4% to 
30% by 0.05% (to plot smooth power curves). I calculated the standard error for the risk 
difference in each potential study outcome using the formula:  
𝑆𝐸(𝑟𝑖𝑠𝑘  𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒) = ඨ
𝑎(𝑁ଵ − 𝑎)
𝑁ଵଷ
+
𝑏(𝑁଴ − 𝑏)
𝑁଴ଷ
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Where 𝑎 is the number of expected events in the comparison group, 𝑁ଵ is the number of patients 
in the comparison group, 𝑏 is the number of expected events in the referent group, and 𝑁଴ is the 
number of patients in the referent group.  
For both aims, once the expected data has been generated, then power is then the 
probability that the lower confidence interval from the potential study outcome exceeds zero. 
This probability is equal to the probability that an observation in a standard normal distribution 
exceeds -d, where -d is the number of standard errors the lower confidence limit is above zero:94    
𝑃𝑜𝑤𝑒𝑟 = Φ ቈ
Θ − 1.96 ∗ 𝑆𝐸(Θ)
𝑆𝐸(Θ) ቉ 
Where Φ(. ) is the cumulative distribution function for a standard normal distribution and Θ is 
the parameter of interest, that is, the rate ratio for Specific Aim 1 and the risk difference for 
Specific Aim 2.  
Statistical power calculations for marginal structural models have not been developed. 
The precision for weighted models decreases as the variability in the weights increases. In prior 
applications of marginal structural models, the variance inflation factor has ranged from 1.1 to 
2.0.23,95-98 To account for the use of marginal structural models and their influence on the power 
available to address the specific aims in this dissertation, the variance of potential study 
outcomes were multiplied by 4, a very conservative assumption about the potential for variance 
inflation in these analyses.  
 
1.  Results: Specific Aim 1 
The crude rate ratio under the proposed scenario would have an approximate variance of 
[1/(0.32*918) + 1/(0.68*918)] = 0.0050 and an expected 95% confidence interval of 0.36, 0.64. 
The power for the naïve analysis was >99%. A conservative assumption that the variance 
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inflation factor could have been as high as 4, yielded an expected 95% confidence interval in the 
weighted model of 0.22, 0.78. This was associated with a power of 94%.  
 
SAS code:  
data a; 
   /*variance for a rate is 1/a+1/b*/ 
   var=1/(0.32*918)+1/(0.68*918); 
   se=sqrt(var); 
   lo=0.50-1.96*se; 
   hi=0.50+1.96*se; 
   z=lo/se; 
   p=cdf('normal',z); 
   run; 
proc print data=a noobs;  
   run; 
 
/*incorporate variance inflation factor*/ 
data a; 
   /*variance for a rate is 1/a+1/b*/ 
   var=(1/(0.32*918)+1/(0.68*918))*4; 
   se=sqrt(var); 
   lo=0.50-1.96*se; 
   hi=0.50+1.96*se; 
   z=lo/se; 
   p=cdf('normal',z); 
   run; 
proc print data=a noobs;  
   run; 
 
 
2.  Results: Specific Aim 2 
Given the sample size, I had 80% power to detect a 10-year risk difference of 2.2% 
comparing black patients to white patients, a risk difference of 3.3% comparing Hispanic 
patients to white patients, and a risk difference of 2.8% comparing women to men. The power 
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curves for a range of possible outcomes for Specific Aim 2, as well as the SAS code to produce 
them, are below.  
 
Figure Appendix.1. Power curves for comparing 10-year mortality risk difference for black 
versus white ART initiators in the CNICS 
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Figure Appendix.2. Power curves for comparing 10-year mortality risk difference for Hispanic 
versus white ART initiators in the CNICS 
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Figure Appendix. 3. Power curves for comparing 10-year mortality risk difference for female 
versus male ART initiators in the CNICS 
 
 
SAS Code: 
data x;  
   /*input the estimated number of persons in each exposure group*/ 
   input white black hisp men women;  
   cards; 
      4685 3911 1421 8159 1858  
   ;; 
   run; 
 
/*recall formulas for standard error of a risk and of a risk difference 
se(risk) = sqrt[R*(1-R)/n]; 
se(risk difference) = sqrt[(a*(N1-a)/N1^3) + (b*(N0-b)/N0^3)];*/ 
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data x;  
   set x; 
   /*vary the risk in the referent group (white or male) between 10 and 20%*/ 
   do risk = .1 to .2 by .05;  
      /*calculate the expected number of events in the referent group*/ 
      b_white = risk*white; 
      b_men = risk*men; 
      /*vary the expected risk difference from -4% to 30%*/ 
      do RD = -.04 to .3 by .0005;    
         /*calculate the expected number of events in each comparison group*/ 
         a_black = (RD+risk)*black; 
         a_hisp = (RD+risk)*hisp; 
         a_women = (RD+risk/men)*women; 
         /*get the standard error for each estimate*/ 
         se_RD_black = sqrt((a_black*(black-a_black)/(black**3))+ 
                (b_white*(white-b_white)/(white**3))); 
         se_RD_hisp  = sqrt((a_hisp *(hisp -a_hisp )/(hisp **3))+ 
                (b_white*(white-b_white)/(white**3))); 
         se_RD_women = sqrt((a_women*(women-a_women)/(women**3))+ 
               (b_men*(men-b_men)/(men**3))); 
         /*convert standard error to power*/ 
         power_black = cdf('normal',(rd-1.96*se_RD_black)/se_RD_black,0,1); 
         power_hisp = cdf('normal',(rd-1.96*se_RD_hisp)/se_RD_hisp,0,1); 
         power_women = cdf('normal',(rd-1.96*se_RD_women)/se_RD_women,0,1); 
         output; 
      end; 
   end; 
   run; 
 
/*define general graphics preferences*/ 
goptions reset=all device=zpng ftext="Albany AMT" htext=12pt gsfname=grafout 
gsfmode=replace xmax=4 ymax=4 xpixels=4000 ypixels=4000; *1000dpi; 
axis1 label=(angle=90 "Power") order=(0 to 1 by .2) w=8  
   major=(w=8 h=18) minor=none offset=(0,0); 
axis2 label=("Risk Difference") order=(-0.02 to .05 by .01) value=(angle=90) w=8  
   major=(w=8 h=7) minor=none offset=(0,0); 
symbol1 c=black v=none i=stepjs w=12 l=22; 
symbol2 c=black v=none i=stepjs w=12 l=24; 
symbol3 c=black v=none i=stepjs w=12 l=1; 
legend1  
   noframe  
   across=1  
   shape=line(120)  
   origin=(300,325)  
   position=(inside)  
   mode=protect 
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   value=(justify=left " 0.10" " 0.15" " 0.20")  
   label=(j=l  position=top  “10-yr  risk,  white”); 
 
/*plot power for black vs white comparisons – lines for each of 3 baseline risks, x-axis is risk 
difference, y-axis is power*/ 
filename grafout "&dir.\power_black.png"; 
proc gplot data=x;  
   plot power_black*RD=risk/vaxis=axis1 haxis=axis2 legend=legend1 noframe;  
   run;  
   quit; 
 
/*plot power for Hispanic vs white comparisons*/ 
filename grafout "&dir.\power_hisp.png"; 
proc gplot data=x;  
   plot power_hisp*RD=risk/vaxis=axis1 haxis=axis2 legend=legend1 noframe;  
   run;  
   quit; 
 
/*plot power for women vs men comparisons*/ 
legend1  
   noframe  
   across=1  
   shape=line(120)  
   origin=(300,325)  
   position=(inside)  
   mode=protect 
   value=(justify=left " 0.10" " 0.15" " 0.20")  
   label=(j=l  position=top  “10-yr  risk,  white”); 
filename grafout "&dir.\power_women.png"; 
proc gplot data=x;  
   plot power_women*RD=risk/vaxis=axis1 haxis=axis2 legend=legend1 noframe;  
   run;  
   quit; 
 
/*examine specific values for risk difference associated with specific power values*/ 
proc print data=x noobs;  
   where round(risk,.01)=0.15 and 0.75 <= power_black <= 0.85;  
   var rd power_black;  
   run; 
 
proc print data=x noobs;  
   where round(risk,.01)=0.15 and 0.75 <= power_hisp <= 0.85;  
   var rd power_hisp;  
   run; 
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proc print data=x noobs;  
   where round(risk,.01)=0.15 and 0.75 <= power_women <= 0.85;  
   var rd power_women;  
   run; 
 
run; quit; run; 
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